AU8199998A - Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue - Google Patents

Description

WO99/02694 PCT/AU98/00530 TITLE "NUCLEIC ACID SEQUENCE AND METHOD FOR SELECTIVELY EXPRESSING A PROTEIN IN A TARGET CELL OR TISSUE" 5 FIELD OF THE INVENTION THIS INVENTION relates generally to gene therapy. More particularly, the present invention 10 relates to a synthetic nucleic acid sequence and to a method for selectively expressing a protein in a target cell or tissue in which at least one existing codon of a parent nucleic acid sequence encoding the protein has been replaced with a synonymous codon. 15 The invention also relates to production of virus particles using one or more synthetic nucleic acid sequences and the method according to the invention. BACKGROUND OF THE INVENTION 20 While gene therapy is of great clinical interest for treatment of gene defects, this therapy has not entered into mainstream clinical practice because selective delivery of genes to target tissues 25 has proven extremely difficult. Currently, viral vectors are used, particularly retroviruses and adenovirus, which are to some extent selective. However, many vector systems are by their nature unable to produce stable integrants and some also 30 invoke immune responses thereby preventing effective treatment. Alternatively, "naked" DNA is packaged in liposomes or other similar delivery systems. A major WO99/02694 PCT/AU98/00530 2 problem to be overcome is that such gene delivery systems themselves are not tissue selective, whereas selective targeting of genes to particular tissues would be desirable for many disorders (e.g., cancer 5 therapy). While use of tissue specific promoters to target gene therapy has been effective in some animal models it has proven less so in man, and selective tissue specific promoters are not available for a wide range of tissues. 10 The current invention has arisen unexpectedly from recent investigations exploring why papillomavirus (PV) late gene expression is restricted to differentiated keratinocytes. In this regard, it is known that PV late genes L1 and L2 are only 15 expressed in non-dividing differentiated keratinocytes (KCs). Many investigators including the present inventors have been unable to detect significant PV L1 and L2 protein expression when these genes are transduced or transfected into undifferentiated 20 cultured cells, using a range of conventional constitutive viral promoters including retroviral long terminal repeats (LTRs) and the strong constitutive promoters of CMV and SV40. PV L1 mRNA can however be efficiently 25 translated in vitro using rabbit reticulocyte cell lysate, suggesting that there are no cellular inhibitors in the lysate interfering with translation of L1. The major difference between the in vitro and in vivo translation systems is that L1 comprises the 30 dominant L1 mRNA in in vitro translation reactions, while it constitutes a minor fraction among the cellular mRNAs in intact cells.

WO99/02694 PCT/AU98/00530 3 In vivo, PV late proteins are not produced in undifferentiated KC. However, they are expressed in large quantity in highly differentiated KC. The mechanism of this tight control of late gene 5 expression has been poorly understood, and searches by many groups for KC specific PV gene transcriptional control proteins have been unrewarding. Blockage to translation of L1 mRNA in vivo has been attributed to sequences within the L1 ORF 10 (Tan et al. 1995, J. Virol. 69 5607-5620; Tan and Schwartz, 1995, J. Virol. 69 2932-2945). By using a Rev and Rev-responsive element of HIV, such inhibition could be overcome (Tan et al. 1995, supra). Accordingly, the inventors examined whether removal of 15 putative "inhibitory sequences" in the L1 ORF would allow production of L1 protein in undifferentiated cells. Deletion mutagenesis of BPV L1 to remove putative inhibitory sequences and expression of resultant deletion mutants in CV-1 cells revealed 20 surprisingly that despite expression of L1 mRNA, L1 protein could not be detected. In view of the foregoing, it has been difficult hitherto to understand how papillomaviruses produce large amounts of L1 protein in the late stage 25 of their life cycle using this apparently "untranslatable" gene. Surprisingly, however, it has now been discovered that PV L1 protein can be produced at substantially enhanced levels in an undifferentiated 30 host cell by replacing existing codons of a native L1 gene with synonymous codons used at relatively high frequency by genes of the undifferentiated host cell WO99/02694 PCT/AU98/00530 4 compared to the existing codons. It has also been found unexpectedly that there are substantial differences in the relative abundance of particular isoaccepting transfer RNAs (tRNAs) in different cells 5 or tissues and this plays a pivotal role in protein expression from a gene with a given codon usage or composition. This discovery has been reduced to practice in synthetic nucleic acid sequences and generic methods, which utilize codon alteration as a 10 means for targeting expression of a protein to particular cells or tissues or alternatively, to cells in a specific state of differentiation. OBJECT OF THE INVENTION 15 It is therefore an object of the present invention to provide a synthetic nucleic acid sequence and a method for selectively expressing a protein in a target cell or tissue which sequence and method 20 ameliorate at least some of the disadvantages associated with the prior art. SUMMARY OF THE INVENTION 25 Accordingly, in one aspect of the invention, there is provided a synthetic nucleic acid sequence capable of selectively expressing a protein in a target cell or tissue of a mammal, wherein said selective expression is effected by replacing at least 30 one existing codon of a parent nucleic acid sequence with a synonymous codon to form said synthetic nucleic acid sequence.

WO99/02694 PCT/AU98/00530 5 Suitably, said synonymous codon corresponds to an iso-tRNA which, when compared to an iso-tRNA corresponding to the at least one existing codon, is in higher abundance in the target cell or tissue 5 relative to one or more other cells or tissues of the mammal. Preferably, said synonymous codon corresponds to an iso-tRNA which, when compared to an iso-tRNA corresponding to the at least one existing 10 codon, is in higher abundance in the target cell or tissue relative to a precursor cell or tissue. Alternatively, said synonymous codon corresponds to an iso-tRNA which, when compared to an iso-tRNA corresponding to the at least one existing 15 codon, is in higher abundance in the target cell or tissue relative to a cell or tissue derived therefrom. Advantageously, said corresponding iso-tRNA in said target cell or tissue is at a level which is at least 110%, preferably at least 200%, more 20 preferably at least 500%, and most preferably at least 1000%, of that expressed in the or each other cell or tissue of the mammal. Alternatively, the synonymous codon may be selected from the group consisting of (1) a codon used 25 at relatively high frequency by genes, preferably highly expressed genes, of the target cell or tissue, (2) a codon used at relatively high frequency by genes, preferably highly expressed genes, of the or each other cell or tissue, (3) a codon used at 30 relatively high frequency by genes, preferably highly expressed genes, of the mammal, (4) a codon used at relatively low frequency by genes of the target cell WO99/02694 6 PCT/AU98/00530 6 or tissue, (5) a codon used at relatively low frequency by genes of the or each other cell or tissue, (6) a codon used at relatively low frequency by genes of the mammal, (7) a codon used at relatively 5 high frequency by genes of another organism, and (8) a codon used at relatively low frequency by genes of another organism. In a preferred embodiment, the at least one existing codon and the synonymous codon are preferably 10 selected such that said protein is expressed from said synthetic nucleic acid sequence in said target cell or tissue at a level which is at least 110%, preferably at least 200%, more preferably at least 500%, and most preferably at least 1000%, of that expressed from said 15 parent nucleic acid sequence in said target cell or tissue. In another aspect, the invention resides in a method for selectively expressing a protein in a target cell or tissue of a mammal, wherein said 20 selective expression is effected by replacing at least one existing codon of a parent nucleic acid sequence with a synonymous codon to form said synthetic nucleic acid sequence. Preferably, the method is further 25 characterized by the steps of: (a) replacing at least one existing codon of a parent nucleic acid sequence encoding said protein with a synonymous codon to produce a synthetic nucleic acid sequence having altered translational 30 kinetics compared to said parent nucleic acid sequence such that said protein is selectively expressible in said target cell or tissue; WO99/02694 PCT/AU98/00530 7 (b) administering to the mammal and introducing into said target cell or tissue, or a precursor cell or precursor tissue thereof, said synthetic nucleic acid sequence operably linked to one 5 or more regulatory nucleotide sequences; and (c) selectively expressing said protein in said target cell or tissue. Preferably, the method further includes, prior to step (a): 10 (i) measuring relative abundance of different isoacceptor transfer RNAs in said target cell or tissue, and in one or more other cells or tissues of the mammal; and (ii) identifying said at least one 15 existing codon and said synonymous codon based on said measurement, wherein said synonymous codon corresponds to an iso-tRNA which, when compared to an iso-tRNA corresponding to the existing codon, is in higher abundance in said target cell or tissue relative to 20 the or each other cell or tissue of the mammal. Suitably, step (ii) above is further characterized in that said synonymous codon corresponds to an iso-tRNA which, when compared to an iso-tRNA corresponding to the at least one existing 25 codon, is in higher abundance in the target cell or tissue relative to a precursor cell or tissue. Alternatively, step (ii) above is further characterized in that said synonymous codon corresponds to an iso-tRNA which, when compared to an 30 iso-tRNA corresponding to the at least one existing codon, is in higher abundance in the target cell or tissue relative to a cell or tissue derived therefrom.

WO 99/02694 PCT/AU98/00530 8 Alternatively, the method further includes, prior to step (a), identifying said at least one existing codon and said synonymous codon based on respective relative frequencies of particular codons 5 used by genes selected from the group consisting of (I) genes of the target cell or tissue, (II) genes of the or each other cell or tissue, (III) genes of the mammal, and (IV) genes of another organism. In yet another aspect, the invention 10 provides a method for expressing a protein in a target cell or tissue from a first nucleic acid sequence including the steps of: introducing into said target cell or tissue, or a precursor cell or precursor tissue 15 thereof, a second nucleic acid sequence encoding at least one isoaccepting transfer RNA wherein said second nucleic acid sequence is operably linked to one or more regulatory nucleotide sequences, and wherein said at least one isoaccepting transfer RNA is 20 normally in relatively low abundance in said target cell or tissue and corresponds to a codon of said first nucleic acid sequence. In a further aspect, the invention extends to a method for producing a virus particle in a 25 cycling eukaryotic cell, said virus particle comprising at least one protein necessary for assembly of said virus particle, wherein said at least one protein is not expressed in said cell from a parent nucleic acid sequence at a level sufficient to permit 30 virus assembly therein, said method including the steps of: WO99/02694 PCT/AU98/00530 9 (a) replacing at least one existing codon of said parent nucleic acid sequence with a synonymous codon to produce a synthetic nucleic acid sequence having altered translational kinetics compared to said 5 parent nucleic acid sequence such that said at least one protein is expressible from said synthetic nucleic acid sequence in said cell at a level sufficient to permit virus assembly therein; (b) introducing into said cell or a 10 precursor thereof said synthetic nucleic acid sequence operably linked to one or more regulatory nucleotide sequences; and (c) expressing said at least one protein in said cell in the presence of other viral proteins 15 required for assembly of said virus particle to thereby produce said virus particle. In yet a further aspect of the invention, there is provided a method for producing a virus particle in a cycling cell, said virus particle 20 comprising at least one protein necessary for assembly of said virus particle, wherein said at least one protein is not expressed in said cell from a parent nucleic acid sequence at a level sufficient to permit virus assembly therein, and wherein at least one 25 existing codon of said parent nucleic acid sequence is rate limiting for the production said at least one protein to said level, said method including the step of introducing into said cell a nucleic acid sequence capable of expressing therein an isoaccepting transfer 30 RNA specific for said at least one codon.

WO99/02694 10 PCT/AU98/00530 BRIEF DESCRITPION OF THE DRAWINGS Figure 1A depicts the nucleotide sequence (SEQ ID NO:l) and deduced amino acid sequence (SEQ ID 5 NO:2) of BPV1 L1. Amino acids (in single letter code) are presented below the second nucleotide of each codon. Mutations introduced into the genes are indicated above the corresponding nucleotides of the original sequence. Horizontal lines indicate the 10 sites and enzymes used for cloning. This replacement of nucleotides resulted in a nucleic acid sequence encoding BPV-1 L1 polypeptide with an amino acid sequences identical to the wild type, but having synonymous codons that are frequently used by 15 mammalian genes. Figure 1B shows the nucleotide sequence (SEQ ID NO:5) and deduced amino acid sequence (SEQ ID NO:6) relating to BPV1 L2 ORF. Amino acids (in single letter code) are presented below the second nucleotide 20 of each codon. Mutations introduced into the genes are indicated above the corresponding nucleotides of the original sequence. Horizontal lines indicate the sites and enzymes used for cloning. This replacement of nucleotides resulted in a nucleic acid sequence 25 encoding BPV-1 L2 polypeptide with an amino acid sequences identical to the wild type, but having synonymous codons that are frequently used by mammalian genes. Figure 1C depicts the nucleotide sequence 30 (SEQ ID NO:9) and deduced amino acid sequence (SEQ ID NO:O10) of green fluorescent protein (GFP). Amino acids (in single letter code) are presented below the SUBSTITUTE SHEET(RULE 26) WO99/02694 11 PCT/AU98/00530 second nucleotide of each codon. Mutations introduced into the genes are indicated above the corresponding nucleotides of the original sequence. Horizontal lines indicate the sites and enzymes used for cloning. 5 This replacement of nucleotides resulted in a nucleic acid sequence encoding GFP polypeptide with an amino acid sequence identical to the native sequence modified for optimal expression in eukaryotic cells, but having synonymous codons that are frequently used 10 by papillomavirus genes. Figure 2A shows detection of L1 protein expressed from synthetic and wild type BPV1 L1 genes. Cos-1 cells were transfected with a synthetic L1 expression plasmid pCDNA/HBL1, and a wild type L1 15 expression plasmid pCDNA/BPVLlwt. The expression of L1 was detected by immunofluorescent staining. Cells were fixed after 36 hrs and incubated with rabbit anti-BPVl L1 antiserum, followed by FITC-conjugated goat anti-rabbit IgG antibody. 20 Figure 2B shows detection by Western blot of L1 protein from Cos-1 cells transfected with pCDNA/HBL1 and pCDNA/BPVLlwt. Figure 2C shows a Northern blot in which L1 mRNA extracted from transfected cells was probed with 25 2 P-labeled probes produced from wild type L1 sequence. The amount of mRNA loaded in respective lanes was examined by hybridization of the mRNA sample with a gapdh probe. Figure 3A shows detection of L2 protein 30 expressed from synthetic and wild type BPV1 L2 genes. Cos-1 cells were transfected with a synthetic L2 expression plasmid pCDNA/HBL2, and a wild type L2 SUBSTITUTE SHEET(RULE 26) WO 99/02694 12 PCT/AU98/00530 expression plasmid pCDNA/BPVL2wt. The expression of L2 was detected by immunofluorescent staining. Cells were fixed after 36 hrs and incubated with rabbit anti-BPVl L2 antiserum, followed by FITC-conjugated 5 goat anti-rabbit IgG antibody. Figure 3B shows detection by Western blot of L2 protein from Cos-i cells transfected with pCDNA/HBL2 and pCDNA/BPVL2wt. Figure 3C shows a Northern blot in which L2 10 mRNA extracted from transfected cells was probed with 2 P-labeled probes produced from wild type L2 sequence. The amount of mRNA loaded in respective lanes was examined by hybridization of the mRNA sample with a gapdh probe. 15 Figure 4 shows in vitro translation of BPVL1 sequences, wild type BPVL1 (wt) or synthetic L1 (HB) using rabbit reticulocyte lysate or wheat germ extract in the presence of 35 S-methionine. In the top panel, wt L1 or HB L1 plasmid DNA was added to the T7 20 DNA polymerase-coupled in vitro translation system. L1 protein was detected by Western blot analysis. In the bottom panel, the translation efficiency of wt L1 or HB L1 sequences in the presence or absence of tRNA was compared. Translation was carried out in rabbit 25 reticulocyte lysate (rabbit) or wheat germ extract (wheat), and samples were collected every two minutes starting from minute 8. Left side of lower panel indicates if 10 - M bovine liver or yeast tRNA was supplied. 30 Figure 5A is a schematic representation of plasmids used to determine L2 expression from BPV cryptic promoter(s). The wild type L1 sequence and SUBSTITUTE SHEET (RULE 26) WO99/02694 13 PCT/AU98/00530 most of the wild type L2 sequence were deleted from the BPV1 genome by BamHI and HindIII digestion and the remaining BPV1 sequence (in yellow) was cloned into pUC18. Wild type or synthetic humanized L2 sequences 5 (in red) were inserted into the BamHI site of the BPV1 genome. The position of the inserted SV40 ori sequence (in white) is indicated. The plasmid in which modified L2 was used but without SV40 ori sequence was also used as a control. The plasmids 10 were transfected into Cos-1 cells and the expression of L2 protein was determined using BPV1 L2-specific polyclonal antiserum followed by FITC-linked anti rabbit IgG. Figure 5B shows expression of L2 protein 15 from native papillomavirus promoter. The plasmids shown in Figure 5A were used to transfect Cos-1 cells and the expression of L2 protein was determined using BPV1 L2-specific polyclonal antiserum followed by FITC-linked anti rabbit IgG. A mock transfection in 20 which the cells did not receive plasmid was used as control. Figure 6 shows expression of GFP in Cos-1 cells transfected with wild-type gfp (wt) or a synthetic gfp gene carrying codons used at relatively 25 high frequency by papillomavirus genes (p). The mRNA extracted from cells transfected with gfp or P gfp was probed with 2 P-labeled gfp probe and is shown on the right panel, using gapdh as a reference gene. Figure 7 shows the expression pattern of 30 GFP in vivo from wild-type gfp gene, or a synthetic gfp gene carrying codons used at relatively high frequency by papillomavirus genes. Using a gene gun, SUBSTITUTE SHEET (RULE 26) WO99/02694 14 PCT/AU98/00530 mice were shot with PGFP (left panel) and GFP (right panel) expression plasmids encoding GFP protein. A transverse section of the mouse skin section shows where the gfp gene is expressed. Bright-field 5 photographs of the same section where dermis (D) epidermis (E) are highlighted are shown to identify the location of fluorescence in the epidermis. Arrows indicate fluorescent signals. 10 DETAILED DESCRIPTION The present invention arises from the unexpected discovery that the relative abundance of different isoaccepting transfer RNAs varies in 15 different cells or tissues, or alternatively in cells or tissues in different states of differentiation or in different stages of the cell cycle, and that such differences may be exploited together with codon composition of a gene to regulate and direct 20 expression of a protein to a particular cell or tissue, or alternatively to a cell or tissue in a specific state of differentiation or in a specific stage of the cell cycle. According to the present invention, this selective targeting is effected by 25 replacing at least one existing codon of a parent nucleic acid sequence encoding the protein with a synonymous codon. Replacement of synonymous codons for existing codons is not new per se. In this regard, we 30 refer to International Application Publication No WO 96/09378 which utilizes such substitution to provide a method of expressing proteins of eukaryotic and viral SUBSTITUTE SHEET (RULE 26) WO99/02694 15 PCT/AU98/00530 origin at high levels in in vitro mammalian cell culture systems, the main thrust of the method being the harvesting of such proteins. In distinct contrast, the present invention utilizes substitution 5 of one or more codons in a gene for targeting expression of the gene to particular cells or tissues with the ultimate aim of facilitating gene therapy as described herein. The term "synonymous codon" as used herein 10 refers to a codon having a different nucleotide sequence to an existing codon but encoding the same amino acid as the existing codon. By "isoaccepting transfer RNA" is meant one or more transfer RNA molecules that differ in their 15 anticodon structure but are specific for the same amino acid. Throughout this specification, unless the context requires otherwise, the words "comprise", comprises" and "comprising" will be understood to 20 imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. Selection of synonymous codons 25 Determination of relative abundance of different tRNA species in different cells Advantageously, the synonymous codon corresponds to an iso-tRNA (iso-tRNA) which, when compared to an iso-tRNA corresponding to the at least 30 one existing codon, is in higher abundance in the SUBSTITUTE SHEET(RULE 26) WO 99/02694 16 PCT/AU98/00530 target cell or tissue relative to one or more other cells or tissues of the mammal. Any method for determining the relative abundance of an iso-tRNA in two or more cells or 5 tissues may be employed. For example, such method may include isolating two or more particular cells or tissues from a mammal, preparing an RNA extract from each cell or tissue which extract includes tRNA, and probing each extract respectively with different 10 nucleic acid sequences each being specific for a particular iso-tRNA to determine the relative abundance of an iso-tRNA between the two or more cells or tissues. Suitable methods for isolating particular 15 cells or tissues are well known to those of skill in the art. For example, one can take advantage of one or more particular characteristics of a cell or tissue to specifically isolate the cell or tissue from a heterogeneous population. Such characteristics 20 include, but are not limited to, anatomical location of a tissue, cell density, cell size, cell morphology, cellular metabolic activity, cell uptake of ions such as Ca 2 ", K', and H' ions, cell uptake of compounds such as stains, markers expressed on the cell surface, 25 cytokine expression, protein fluorescence, and membrane potential. Suitable methods that may be used in this regard include surgical removal of tissue, flow cytometry techniques such as fluorescence activated cell sorting (FACS), immunoaffinity 30 separation (e.g., magnetic bead separation such as Dynabead TM separation), density separation (e.g., metrizamide, PercollTM, or FicollTM gradient SUBSTITUTE SHEET(RULE 26) WO99/02694 17 PCT/AU98/00530 centrifugation), and cell-type specific density separation (e.g., Lymphoprep

M

). For example, dividing cells or blast cells may be separated from non dividing cells or resting cells according to cell size 5 by FACS or metrizamide gradient separation. Any suitable method for isolating total RNA from a cell or tissue may be used. Typical procedures contemplated by the invention are described in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Ausubel, et al., eds) 10 (John Wiley & Sons, Inc. 1997), hereby incorporated by reference, at page 4.2.1 through page 4.2.7. Preferably, techniques which favor isolation of tRNA are employed as, for example, described in Brunngraber, E.F. (1962, Biochem. Biophys. Res. 15 Commun. 8:1-3) which is hereby incorporated by reference. The probing of an RNA extract is suitably effected with different oligonucleotide sequences each being specific for a particular iso-tRNA. Of course 20 it will be appreciated that for a given mammal, oligonucleotide sequences would need to be selected which hybridize specifically with particular iso-tRNA sequences expressed by the mammal. Such selection is well within the realm of one of ordinary skill in the 25 art based a known iso-tRNA sequence. For example, in the case of a mouse, exemplary oligonucleotide sequences which may be used include those described in Gauss and Sprinzel (1983, Nucleic Acids Res. 11 (1)) hereby incorporated by reference. In this respect, 30 the oligonucleotide sequences may be selected from the group consisting of: SUBSTITUTE SHEET (RULE 26) WO 99/02694 18 PCT/AU98/00530 5'-TAAGGACTGTAAGACTT-3' (SEQ ID NO:13) for Ala"c 5'-CGAGCCAGCCAGGAGTC-3' (SEQ ID NO:14) for Arg c GA 5'-CTAGATTGGCAGGAATT-3' (SEQ ID NO:15) for Asn c 5 5'-TAAGATATATAGATTAT-3' (SEQ ID NO:16) for AspGAC 5'-AAGTCTTAGTAGAGATT-3' (SEQ ID NO:17) for CysTac 5'-TATTTCTACACAGCATT-3' (SEQ ID NO:18) for GluA 5'-CTAGGACAATAGGAATT-3' (SEQ ID NO:19) for Gln" 5'-TACTCTCTTCTGGGTTT-3' (SEQ ID NO:20) for Gly.A 10 5'-TGCCGTGACTCGGATTC-3' (SEQ ID NO:21) for Hisa c 5'-TAGAAATAAGAGGGCTT-3' (SEQ ID NO:22) for IleATC 5'-TACTTTTATTTGGATTT-3' (SEQ ID NO:23) for LeuTA 5'-TATTAGGGAGAGGATTT-3' (SEQ ID NO:24) for LeuCTT 5'-TCACTATGGAGATTTTA-3' (SEQ ID NO:25) for Lys" 15 5'-CGCCCAACGTGGGGCTC-3' (SEQ ID NO:26) for LysMG 5'-TAGTACGGGAAGGATTT-3' (SEQ ID NO:27) for Met e1n g 5'-TGTTTATGGGATACAAT-3' (SEQ ID NO:28) for PheTTC 5'-TCAAGAAGAAGGAGCTA-3' (SEQ ID NO:29) for Pro c 5'-GGGCTCGTCCGGGATTT-3' (SEQ ID NO:30) for Procc' 20 5'-ATAAGAAAGGAAGATCG-3' (SEQ ID NO:31) for SerAGc 5'-TGTCTTGAGAAGAGAAG-3' (SEQ ID NO:32) for ThrACA 5'-TGGTAAAAAGAGGATTT-3' (SEQ ID NO:33) for TyrTAC 5'-TCAGAGTGTTCATTGGT-3' (SEQ ID NO:34) for ValGTA 25 Typically, the relative abundance of iso tRNA species may be determined by blotting techniques that include a step whereby sample RNA or tRNA extract is immobilized on a matrix (preferably a synthetic membrane such as nitrocellulose), a hybridization 30 step, and a detection step. Northern blotting may be used to identify an RNA sequence that is complementary to a nucleic acid probe. Alternatively, dot blotting SUBSTITUTE SHEET(RULE 26) WO99/02694 19 PCT/AU98/00530 and slot blotting can be used to identify complementary DNA/RNA or RNA/RNA nucleic acid sequences. Such techniques are well known by those skilled in the art, and have been described in 5 Ausubel, et al (supra) at pages 2.9.1 through 2.9.20. According to such methods, a sample of tRNA immobilized on a matrix is hybridized under stringent conditions to a complementary nucleotide sequence (such as those mentioned above) which is labeled, for 10 example, radioactively, enzymatically or fluorochromatically. "Stringency" as used herein, refers to the temperature and ionic strength conditions, and presence or absence of certain organic solvents, 15 during hybridization. The higher the stringency, the higher will be the degree of complementarity between the immobilized nucleotide sequences (i.e., iso-tRNA) and the labeled oligonucleotide sequence. For a discussion of typical stringent conditions that may be 20 used, see CURRENT PROTOCOLS IN MOLECULAR BIOLOGY supra at pages 2.10.1 to 2.10.16, and Sambrook et al in MOLECULAR CLONING. A LABORATORY MANUAL (Cold Spring Harbor Press, 1989), hereby incorporated by reference, at sections 1.101 to 1.104. 25 While stringent washes are typically carried out at temperatures from about 42 0 C to 68 0 C, one skilled in the art will appreciate that other temperatures may be suitable for stringent conditions. Maximum hybridization typically occurs at about 200 to 30 250 below the Tm for formation of a DNA-DNA hybrid. It is well known in the art that the Tm is the melting temperature, or temperature at which two complementary SUBSTITUTE SHEET(RULE 26) WO 99/02694 20 PCT/AU98/00530 nucleic acid sequences dissociate. Methods for estimating Tm are well known in the art (see CURRENT PROTOCOLS IN MOLECULAR BIOLOGY supra at page 2.10.8). Maximum hybridization typically occurs at about 100 to 5 150 below the Tm for a DNA-RNA hybrid. Other stringent conditions are well known in the art. A skilled addressee will recognize that various factors can be manipulated to optimize the specificity of the hybridization. Optimization of the 10 stringency of the final washes can serve to ensure a high degree of hybridization. Methods for detecting labeled nucleotide sequences hybridized to an immobilized nucleotide sequence are well known to practitioners in the art. 15 Such methods include autoradiography, chemiluminescent, fluorescent and colorimetric detection. Advantageously, the relative abundance of an iso-tRNA in two or more cells or tissues may be 20 determined by comparing the respective levels of binding of a labeled nucleotide sequence specific for the iso-tRNA to equivalent amounts of immobilized RNA obtained from the two or more cells or tissues. Similar comparisons are suitably carried out to 25 determine the respective relative abundance of other iso-tRNAs in the two or more cells or tissues. One of ordinary skill in the art will thereby be able to determine a relative tRNA abundance table (see for example TABLE 2) for different cells or tissues. From 30 such comparisons, one or more synonymous codons may be selected such that the or each synonymous codon corresponds to an iso-tRNA which, when compared to an SUBSTITUTE SHEET (RULE 26) WO 99/02694 21 PCT/AU98/00530 iso-tRNA corresponding to an existing codon of the parent nucleic acid sequence, is in higher abundance in the target cell or tissue relative to other cells or tissues of the mammal. 5 Advantageously, a synonymous codon is selected such that its corresponding iso-tRNA in the target cell or tissue is at a level which is at least 110%, preferably at least 200%, more preferably at least 500%, and most preferably at least 1000%, of 10 that expressed in the or each other cell or tissue of the mammal. Suitably, synonymous codons for selective expression of a protein in a differentiated cell, preferably a differentiated keratinocyte, are selected 15 from the group consisting of gca (Ala), cuu (Leu) and cua (Leu). Synonymous codons for selective expression of a protein in an undifferentiated cell, preferably an undifferentiated keratinocyte, are suitably 20 selected from the group consisting of cga (Arg), cci (Pro) and aag (Asn). Analysis of codon usage Alternatively, synonymous codons may be 25 selected by analyzing the frequency at which codons are used by genes expressed in (i) particular cells or tissues, (ii) substantially all cells or tissues of the mammal, or (iii) an organism which may infect particular cells or tissues of the mammal. 30 Codon frequency tables as well as suitable methods for determining frequency of codon usage in an organism are described, for example, in an article by SUBSTITUTE SHEET(RULE 26) WO 99/02694 22 PCT/AU98/00530 Sharp et al (1988, Nucleic Acids Res. 16 8207-8211) which is hereby incorporated by reference. The relative level of gene expression (e.g., detectable protein expression vs no detectable 5 protein expression) can provide an indirect measure of the relative abundance of specific iso-tRNAs expressed in different cells or tissues. For example, a virus may be capable of propagating within a first cell or tissue (which may include a cell or tissue at a 10 specific stage of differentiation) but may be substantially incapable of propagating in a second cell or tissue (which may include a cell or tissue at another stage of differentiation). Comparison of the pattern of codon usage by genes of the virus with the 15 pattern of codon usage by genes expressed in the second cell or tissue may thus provide indirectly a set of synonymous codons which correspond to iso-tRNAs expressed at relatively high abundance in the first cell or tissue relative to the second cell or tissue 20 and vice versa. Simultaneously, the above comparison may also provide indirectly a set of synonymous codons which correspond to iso-tRNAs expressed at relatively high abundance in the second cell or tissue relative to the first cell or tissue. 25 From the foregoing, a synonymous codon according to the invention may correspond to a codon including, but not limited to, (1) a codon used at relatively high frequency by genes, preferably highly expressed genes, of the target cell or tissue, (2) a 30 codon used at relatively high frequency by genes, preferably highly expressed genes, of the or each other cell or tissue, (3) a codon used at relatively SUBSTITUTE SHEET(RULE 26) WO 99/02694 23 PCT/AU98/00530 high frequency by genes, preferably highly expressed genes, of the mammal, (4) a codon used at relatively low frequency by genes of the target cell or tissue, (5) a codon used at relatively low frequency by genes 5 of the or each other cell or tissue, (6) a codon used at relatively low frequency by genes of the mammal, (7) a codon used at relatively high frequency by genes of another organism, and (8) a codon used at relatively low frequency by genes of another organism. 10 For example, codons used at a relatively high frequency by genes, preferably highly expressed genes, of the mammal may be selected from the group consisting of: cuc (Leu) , cuu, (Leu) , cug (Leu), uua (Leu), uug (Leu); cgg (Arg), cgc (Arg), aga (Arg), agg 15 (Arg); agu (Ser), agc (Ser), ucu (Ser), ucc (Ser), and uca (Ser). Alternatively, such codons may include auu (Ile), auc (Ile); guu (Val), guc (Val), gug (Val); acu (Thr), acc (Thr), aca (Thr); gcu (Ala), gcc (Ala), gca (Ala); cag (Glu); ggc (Gly), gga (Gly), ggg (Gly). 20 Codons used at a relatively low frequency by genes of the mammal are described, for example, in Sharp et al (1988, supra). Such codons may comprise cua (Leu); cga (Arg), cgu (Arg); ucg (Ser). Alternatively, such codons may include aua (Ile); gua 25 (Val); acg (Thr); gcg (Ala); caa (Glu); ggu (Gly). Construction of synthetic nucleic acid sequences The step of replacing synonymous codons for existing codons may be effected by any suitable technique. For example, in vitro mutagenesis methods 30 may be employed which are well known to those of skill in the art. Suitable mutagenesis methods are SUBSTITUTE SHEET (RULE 26) WO 99/02694 24 PCT/AU98/00530 described for example in the relevant sections of Ausubel, et al. (supra) and of Sambrook, et al., (supra) which are hereby incorporated by reference. Alternatively, suitable methods for altering DNA are 5 set forth, for example, in U.S. Patent Nos 4,184,917, 4,321,365 and 4,351,901, which are hereby incorporated by reference. Instead of in vitro mutagenesis, the second nucleic acid sequence may be synthesized de novo using readily available machinery. Sequential 10 synthesis of DNA is described, for example, in U.S. Patent No 4,293,652, which is hereby incorporated by reference. However, it should be noted that the present invention is not dependent on and not directed to any one particular technique for replacing 15 synonymous codons for existing codons. It is not necessary to replace all the existing codons of the parent nucleic acid sequence with synonymous codons each corresponding to a iso tRNA expressed in relatively high abundance in the 20 target cell compared to other cells. Increased expression may be accomplished even with partial replacement. Preferably, the replacing step affects 5%, 10%, 15%, 20%, 25%, 30%, more preferably 35%, 40%, 50%, 60%, 70% or more of the existing codons of the 25 parent nucleic acid sequence. The parent nucleic acid sequence is preferably a natural gene. By "natural gene" is meant a gene that naturally encodes the protein. However, it is possible that the parent nucleic acid sequence 30 encodes a protein that is not naturally-occurring but has been engineered using recombinant techniques. SUBSTITUTE SHEET(RULE 26) WO 99/02694 25 PCT/AU98/00530 The parent nucleic acid sequence need not be obtained from the mammal but may be obtained from any suitable source such as from a eukaryotic or prokaryotic organism. For example, the parent nucleic 5 acid sequence may be obtained from another mammal or other animal. Alternatively, the parent nucleic acid sequence may be obtained from a pathogenic organism. In such a case, a natural host of the pathogenic organism is preferably a mammal. For example, the 10 pathogenic organism may be a yeast, bacterium or virus. For example, suitable proteins which may be used for selective expression in accordance with the invention include, but are not limited to the cystic 15 fibrosis transmembrane conductance regulator (CFTR) protein, and adenosine deaminase (ADA). In the case of CFTR, a parent nucleic acid sequence encoding the CFTR protein which may be utilized to produce the synthetic nucleic acid sequence is described, for 20 example, in Riordan et al (1989, Science 245 1066 1073), and in the GenBank database under Accession No. HUMCFTRM, which are hereby incorporated by reference. The term "nucleic acid sequence" as used herein designates mRNA, RNA, cRNA, cDNA or DNA. 25 Regulatory nucleotide sequences which may be utilized to regulate expression of the synthetic nucleic acid sequence include, but are not limited to, a promoter, an enhancer, and a transcriptional terminator. Such regulatory sequences are well known 30 to those of skill in the art. Synthetic nucleic acid sequences according to the invention may be operably linked to one or more SUBSTITUTE SHEET (RULE 26) WO 99/02694 26 PCT/AU98/00530 regulatory sequences in the form of an expression vector. By "vector" is meant a nucleic acid molecule, preferably a DNA molecule derived, for example, from a plasmid, bacteriophage, or mammalian or insect virus, 5 into which a synthetic nucleic acid sequence may be inserted or cloned. A vector preferably contains one or more unique restriction sites and may be capable of autonomous replication in a defined host cell including the target cell or tissue or a precursor 10 cell or precursor tissue thereof, or be integratable with the genome of the defined host such that the cloned sequence is reproducible. Thus, by "expression vector" is meant any autonomous element capable of directing the synthesis of a protein. Such expression 15 vectors are well known by practitioners in the art. The term "precursor cell" as used herein refers to a cell that gives rise to the target cell. The invention also contemplates synthetic nucleic acid sub-sequences encoding desired portions 20 of the protein. A nucleic acid sub-sequence encodes a domain of the protein having a function associated therewith and preferably encodes at least 10, 20, 50, 100, 150, or 500 contiguous amino acids of the protein. 25 The step of introducing the synthetic nucleic acid sequence into a target cell will differ depending on the intended use and or species, and may involve non-viral and viral vectors, cationic liposomes, retroviruses and adenoviruses such as, for 30 example, described in Mulligan, R.C., (1993 Science 260 926-932) which is hereby incorporated by reference. Such methods may include: SUBSTITUTE SHEET (RULE 26) WO 99/02694 27 PCT/AU98/00530 (i) Local application of the synthetic nucleic acid sequence by injection (Wolff et al., 1990, Science 247 1465-1468, which is hereby incorporated by reference), surgical implantation, 5 instillation or any other means. This method may also be used in combination with local application by injection, surgical implantation, instillation or any other means, of cells responsive to the protein encoded by the synthetic nucleic acid sequence so as 10 to increase the effectiveness of that treatment. This method may also be used in combination with local application by injection, surgical implantation, instillation or any other means, of another factor or factors required for the activity of said protein. 15 (ii) General systemic delivery by injection of DNA, (Calabretta et al., 1993, Cancer Treat. Rev. 19 169-179, which is hereby incorporated by reference), or RNA, alone or in combination with liposomes (Zhu et al., 1993, Science 261 209-212, 20 which is hereby incorporated by reference), viral capsids or nanoparticles (Bertling et al., 1991, Biotech. Appl. Biochem. 13 390-405, which is hereby incorporated by reference) or any other mediator of delivery. Improved targeting might be achieved by 25 linking the synthetic nucleic acid sequence to a targeting molecule (the so-called "magic bullet" approach employing for example, an antibody), or by local application by injection, surgical implantation or any other means, of another factor or factors 30 required for the activity of the protein produced from said synthetic nucleic acid sequence, or of cells responsive to said protein. SUBSTITUTE SHEET(RULE 26) WO 99/02694 28 PCT/AU98/00530 (iii) Injection or implantation or delivery by any means, of cells that have been modified ex vivo by transfection (for example, in the presence of calcium phosphate: Chen et al., 1987, Mole. Cell 5 Biochem. 7 2745-2752, or of cationic lipids and polyamines: Rose et al., 1991, BioTech. 10 520-525, which articles are hereby incorporated by reference), infection, injection, electroporation (Shigekawa et al., 1988, BioTech. 6 742-751, which is hereby 10 incorporated by reference) or any other way so as to increase the expression of said synthetic nucleic acid sequence in those cells. The modification may be mediated by plasmid, bacteriophage, cosmid, viral (such as adenoviral or retroviral; Mulligan, 1993, 15 Science 260 926-932; Miller, 1992, Nature 357 455-460; Salmons et al., 1993, Hum. Gen. Ther. 4 129-141, which articles are hereby incorporated by reference) or other vectors, or other agents of modification such as liposomes (Zhu et al., 1993, Science 261 209-212, 20 which is hereby incorporated by reference), viral capsids or nanoparticles (Bertling et al., 1991, Biotech. Appl. Biochem. 13 390-405, which is hereby incorporated by reference), or any other mediator of modification. The use of cells as a delivery vehicle 25 for genes or gene products has been described by Barr et al., 1991, Science 254 1507-1512 and by Dhawan et al., 1991, Science 254 1509-1512, which articles are hereby incorporated by reference. Treated cells may be delivered in combination with any nutrient, growth 30 factor, matrix or other agent that will promote their survival in the treated subject. SUBSTITUTE SHEET (RULE 26) WO 99/02694 29 PCT/AU98/00530 In yet another aspect, the invention provides a pharmaceutical composition comprising the synthetic nucleic sequences of the invention and a pharmaceutically acceptable carrier. 5 By "pharmaceutically-acceptable carrier" is meant a solid or liquid filler, diluent or encapsulating substance that may be safely used in systemic administration. Depending upon the particular route of administration, a variety of 10 pharmaceutically acceptable carriers, well known in the art may be used. These carriers may be selected from a group including sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, 15 phosphate buffered solutions, emulsifiers, isotonic saline, and pyrogen-free water. Any suitable technique may be employed for determining expression of the protein from said synthetic nucleic acid sequence in a particular cell 20 or tissue. For example, expression can be measured using an antibody specific for the protein of interest or portion thereof. Such antibodies and measurement techniques are well known to those skilled in the art. Applications 25 In one embodiment of the present invention, the target cell is suitably a differentiated cell. Advantageously, the protein which is desired to be selectively expressed in the differentiated cell is not expressible in a precursor cell thereof (such as 30 an undifferentiated or less differentiated cell of the mammal) from a parent nucleic acid sequence at a level SUBSTITUTE SHEET(RULE 26) WO 99/02694 30 PCT/AU98/00530 sufficient to effect a particular function associated with said protein. In this embodiment, the step of replacing at least one existing codon with a synonymous codon is characterized in that the 5 synonymous codon corresponds to an iso-tRNA which, when compared to the iso-tRNA corresponding to the at least one existing codon, is in relatively higher abundance in the differentiated cell compared to the precursor cell. Accordingly, a synthetic nucleic acid 10 sequence is produced having altered translational kinetics compared to the parent nucleic acid sequence wherein the protein is expressible in the differentiated cell at a level sufficient to effect a particular function associated with said protein, but 15 wherein the protein is not expressible in the precursor cell at a level sufficient to effect said function. As used herein, the term "function" refers to a biological, or therapeutic function. 20 The above embodiment may be utilized advantageously for somatic gene therapy where overexpression of a protein in undifferentiated cells such as stems cells has undesirable consequences including death or differentiation of the stem cells. 25 In such a case, a suitable protein may include cystic fibrosis transmembrane conductance regulator (CFTR) protein, and adenosine deaminase (ADA). The differentiated cell may comprise a cell of any lineage including a cell of epithelial, 30 hemopoetic or neural origin. For example, the differentiated cell may be a mature differentiated keratinocyte. SUBSTITUTE SHEET(RULE 26) WO 99/02694 31 PCT/AU98/00530 Targeting expression of a protein to progeny of a stem cell but not to the stem cell itself The synthetic nucleic acid sequence 5 produced above may be transfected directly into the differentiated cell for the desired function or alternatively, transfected into the precursor cell. For example, in the case of ADA deficiency, expression of ADA in stem cells may result in loss of stem 10 phenotype which is undesirable. However, an advantageous therapy may reside in transducing autologous marrow stem cells with a synthetic nucleic acid sequence operably linked to one or more regulatory sequences, wherein existing codons of the 15 wild type ADA gene have been replaced with synonymous codons each corresponding to an iso-tRNA expressed in relatively high abundance in differentiated lymphocytes compared to the marrow stem cells. The transduced stem cells may then be reinfused into the 20 patient. This approach will result in transduced marrow stem cells which are not capable of expressing ADA themselves, but which are able to give rise to a renewable population of differentiated lymphocytes which are capable of expressing ADA at levels 25 sufficient to permit a therapeutic effect. In this regard, a suitable cell source for this purpose may comprise stem cells isolated as CD34 positive cells from a patient's peripheral blood or marrow. For gene delivery, a suitable vector may include a retrovirus 30 or Adeno associated virus. Alternatively, in the case of inducing cell mediated immunity, dendritic cells are important SUBSTITUTE SHEET(RULE 26) WO 99/02694 32 PCT/AU98/00530 antigen presenting cells (APC) but have a very limited life span for antigen presentation once activated of between 14 to 21 days. Consequently, dendritic cells provide relatively short-term immune stimulation that 5 may not be optimal. However, in accordance with the present invention, a long-term immune stimulation may be provided by transducing autologous bone marrow derived CD34 positive dendritic cell precursors with a synthetic nucleotide sequence encoding an antigen. 10 such as the melanoma antigen MART-1, wherein the synthetic sequence is operably linked to one or more regulatory sequences, and wherein existing codons of a wild type nucleotide sequence encoding MART-1 have been replaced with synonymous codons each 15 corresponding to an iso-tRNA expressed in relatively high abundance in dendritic cells compared to the dendritic cell precursors. The transduced dendritic cell precursors may then be reinfused into the patient. This approach will result in transduced 20 dendritic cell precursors which are not capable of expressing MART-1 themselves, but which are able to give rise to a renewable population of dendritic cells which are capable of expressing MART-1 at levels sufficient to permit a lifelong intermittent 25 restimulation of a cytotoxic T lymphocyte (CTL) response to the MART-1 antigen. Targeting expression of a protein to a stem cell but not to progeny of the stem cell 30 In an alternate embodiment, the target cell may be an undifferentiated cell wherein the protein is not expressible in said undifferentiated cell, from a SUBSTITUTE SHEET(RULE 26) WO 99/02694 33 PCT/AU98/00530 parent nucleic acid sequence encoding the protein, at a level sufficient to effect a particular function associated with the protein. In such a case, at least one existing codon of the parent nucleic acid sequence 5 is replaced with a synonymous codon corresponding to an iso-tRNA which, when compared to the iso-tRNA corresponding to the at least one existing codon, is in relatively higher abundance in the undifferentiated cell compared to a differentiated cell. This results 10 in a synthetic nucleic acid sequence having altered translational kinetics compared to said parent nucleic acid sequence wherein the protein is expressible in the undifferentiated cell at a level sufficient to effect a particular function associated with the 15 protein, but wherein the protein is not expressible in differentiated cells derived from the undifferentiated cell at a level sufficient to effect said function. This alternate embodiment may, by way of example, be used to permit expression of a 20 transcriptional regulatory protein which when expressed in a particular undifferentiated cell or stem cell facilitates differentiation of the stem cell along a particular cell lineage. It will be appreciated that in such a case, the regulatory 25 protein is normally expressed from a gene in which the existing codons correspond to iso-tRNAs which are in relatively low abundance in the stem cell compared to other iso-tRNAs and that therefore the protein is not capable of being expressed at levels sufficient for 30 commitment of the stem cell to differentiate along a particular cell lineage. It will also be apparent that such commitment to differentiate along a SUBSTITUTE SHEET(RULE 26) WO 99/02694 34 PCT/AU98/00530 particular cell lineage may be utilized to prevent production of a particular lineage of cells such as cancer cells. Alternatively, the method according to this 5 embodiment may be used to express a transcriptional regulatory protein that is involved in the production of a therapeutic agent or agents. Such a protein may include, for example, NF-kappa-B transcription factor p65 subunit (NF-kappa-B p65) which is involved in the 10 production of interleukin-2 (IL-2), interleukin-3 (IL 3) and granulocyte and macrophage colony stimulating factor (GMCSF). NF-kappa-B p65 is encoded naturally by a nucleotide sequence comprising a number of existing codons each corresponding to an iso-tRNA expressed in 15 relatively low abundance in stem cells. Accordingly, such sequence may be used as the parent nucleic acid sequence according to this embodiment. A suitable nucleotide sequence encoding this protein is described, for example, in Lyle et al (1994, Gene 138 20 265-266) and in the EMBL database under Accession No HSNFKB65A which are hereby incorporated by reference. A suitable undifferentiated cell which may be utilized in accordance with the present embodiment includes but is not limited to a stem cell, such as a 25 CD34 positive hemopoetic stem cell. The present embodiment may also be used advantageously for gene therapy where ongoing regulated expression of a transgene is desirable. For example, secure but reversible regulation of fertility 30 is desirable in veterinary practice and in humans. Such regulation may be effected by transducing autologous breast ductal epithelial cells with a SUBSTITUTE SHEET(RULE 26) WO 99/02694 35 PCT/AU98/00530 synthetic nucleic acid encoding a leutinising hormone (LH) antagonist or a leutinising hormone releasing hormone (LHRH) antagonist under the control of one or more regulatory sequences. The synthetic nucleic acid 5 may be produced by replacing existing codons of a parent nucleic acid with synonymous codons corresponding to iso-tRNAs expressed in relatively high abundance in resting breast ductal epithelial cells compared to differentiated cells arising 10 therefrom. Once the transduced cells are implanted back into the patient, expression may be switched off by oral administration of progestagen, forcing the differentiation of the majority of the stem cells and loss of expression of the antagonist. Once pregnancy 15 is established, the suppression would be self sustaining by the naturally produced progestagen. The iso-tRNA composition of resting and oestrogen drived breast epithelial cells may be established by first obtaining resting cells from reduction mammoplasty, 20 and determining the cellular tRNA composition in the presence and absence of oestrogen. The synthetic nucleic acid sequence may be introduced into autologous resting epithelial cells by cell electroporation ex vivo, and the transduced cells may 25 be subsequently transplanted subcutaneously into the patient. Progestagen may be administered as required to reverse regulation of fertility. Targeting expression of a toxin to a tumor 30 cell but not to any other cells of the mammal Many toxins and drugs are available that can kill tumor cells. However, these toxins and drugs SUBSTITUTE SHEET(RULE 26) WO 99/02694 36 PCT/AU98/00530 are generally toxic for all dividing cells. This problem may be nevertheless ameliorated by establishing the isoacceptor tRNA composition in a tumor clone, and constructing a synthetic toxin gene 5 (e.g., ricin gene) or a synthetic anti-proliferation gene (e.g., the tumor supressor p53) using synonymous codons corresponding to iso-tRNAs expressed at relatively high abundance in the tumor clone compared to normal dividing cells of the mammal. The synthetic 10 gene is then introduced into the patient by suitable means to selectively express the synthetic genes in tumor cells. Alternatively, a chemotherapy enhancing product gene (i.e., a drug resistance gene e.g., the 15 multi-drug resistance gene) using a codon pattern unlikely to be expressed in the tumor efficiently may be employed. Targeting gene therapy to control body fat 20 Leptins are proteins known to control satiety. By analogy with animal data, however, if too much leptin is administered to a patient, leptin induced starvation might occur. Advantageously, a synthetic gene encoding leptin may be constructed 25 including synonymous codons corresponding to iso-tRNAs expressed at relatively high levels in activated adipocytes compared to non-activated adipocytes. The synthetic gene may then be introduced into the patient by suitable means such that leptin is only expressed 30 substantially in activated adipocytes as opposed to non-activated adipocytes. As body fat turnover diminishes under the influence of leptin reduced SUBSTITUTE SHEET (RULE 26) WO 99/02694 37 PCT/AU98/00530 appetite, the metabolic activity of the adipocytes falls and the leptin production decreases correspondingly. 5 Targeting expression of a protein to a stage of the cell cycle In another embodiment of the invention, the target cell may be a non-cycling cell. In this case, the protein which is desired to be selectively 10 expressed in the non-cycling cell is expressible in a cycling cell of the mammal from a parent nucleic acid sequence at a level sufficient to effect a particular function associated with the protein. The synonymous codons are selected such that each corresponds to an 15 iso-tRNA which, when compared to the iso-tRNA corresponding to the at least one existing codon, is in higher abundance in the non-cycling cell compared to the cycling cell. Accordingly, a synthetic nucleic acid sequence is produced having altered translational 20 kinetics compared to the parent nucleic acid sequence wherein the protein is expressible in the non-cycling cell at a level sufficient to effect a particular function associated with said protein, but wherein the protein is not expressible in the non-cycling cell to 25 effect said function. The term "non-cycling cell" as used herein refers to a cell that has withdrawn from the cell cycle and has entered the GO state. In this state, it is well known that transcription of endogenous genes 30 and protein translation are at substantially reduced levels compared to phases of the cell cycle, namely G1, S, G2 and M. SUBSTITUTE SHEET (RULE 26) WO 99/02694 38 PCT/AU98/00530 By "cycling cell" is meant a cell which is in one of the above phases of the cell cycle. Expressing a protein in a target cell or 5 tissue by in vivo expression of iso-tRNAs in the target cell or tissue In another aspect, the invention extends to a method wherein a protein may be selectively expressed in a target cell by introducing into the 10 cell an auxiliary nucleic acid sequence capable of expressing therein one or more isoaccepting transfer RNAs which are not expressed in relatively high abundance in the cell but which are rate limiting for expression of the protein from a parent nucleic acid 15 sequence to a level sufficient for effecting a function associated with the protein. In this embodiment, introduction of the auxiliary nucleic acid sequence in the cell changes the translational kinetics of the parent nucleic acid sequence such that 20 said protein is expressed at a level sufficient to effect a function associated with the protein. The step of introducing the auxiliary nucleic acid sequence into the target cell or a tissue comprising a plurality of these cells may be effected 25 by any suitable means. For example, analogous methodologies for introduction of the synthetic nucleic acid sequence referred to above may be employed for delivery of the auxiliary nucleic acid sequence into said cycling cell. 30 SUBSTITUTE SHEET(RULE 26) WO 99/02694 3 9 PCT/AU98/00530 Assembly of virus particles in cells which do not normally permit assembly of virus particles In yet another aspect, the invention extends to a method for producing a virus particle in 5 a cycling eukaryotic cell. The virus particle will comprise at least one protein necessary for virus assembly, wherein the at least one protein is not expressed in the cell from a parent nucleic acid sequence at a level sufficient to permit virus 10 assembly therein. This method is characterized by replacing at least one existing codon of the parent nucleic acid sequence with a synonymous codon to produce a synthetic nucleic acid sequence having altered translational kinetics compared to the parent 15 nucleic acid sequence such that the at least one protein is expressible from the synthetic nucleic acid sequence in the cell at a level sufficient to permit virus assembly therein. The synthetic nucleic acid sequence so produced is operably linked to one or more 20 regulatory nucleotide sequences and is then introduced into the cell or a precursor cell thereof. The at least one protein is expressed subsequently in the cell in the presence of other viral proteins required for assembly of the virus particle to thereby produce 25 the virus particle. Advantageously, the synonymous codon corresponds to an iso-tRNA expressed at relatively high level in the cell compared to the iso-tRNAs corresponding to the existing codons. 30 The cycling cell may be any cell in which the virus is capable of replication. Suitably, the cycling cell is a eukaryotic cell. Preferably, the SUBSTITUTE SHEET (RULE 26) WO 99/02694 40 PCT/AU98/00530 cycling cell for production of the virus particle is a eukaryotic cell line capable of being grown in vitro such as, for example, CV-1 cells, COS cells, yeast or spodoptera cells. 5 Suitably, the at least one protein of the virus particle are viral capsid proteins. Preferably, the viral capsid proteins comprise L1 and/or L2 proteins of papillomavirus. The other viral proteins required for 10 assembly of the virus particle in the cell may be expressed from another nucleic acid sequence(s) which suitably contain the rest of the viral genome. In the case of the at least one protein comprising L1 and/or L2 of papillomavirus, said other nucleic acid 15 sequence(s) preferably comprises the papillomavirus genome without the nucleotide sequences encoding L1 and/or L2. In yet a further aspect of the invention, there is provided a method for producing a virus 20 particle in a cycling cell, said virus particle comprising at least one protein necessary for assembly of said virus particle, wherein said at least one protein is not expressed in said cell from a parent nucleic acid sequence at a level sufficient to permit 25 virus assembly therein, and wherein at least one existing codon of said parent nucleic acid sequence is rate limiting for the production said at least one protein to said level, said method including the step of introducing into said cell a nucleic acid sequence 30 capable of expressing therein an isoaccepting transfer RNA specific for said at least one codon. SUBSTITUTE SHEET(RULE 26) WO 99/02694 4 1 PCT/AU98/00530 In yet a further aspect, the invention resides in virus particles resulting from the above methods. The invention further contemplates cells or 5 tissues containing therein the synthetic nucleic acid sequences of the invention, or alternatively, cells or tissues produced from the methods of the invention. The invention is further described with reference to the following non-limiting examples. 10 EXAMPLE 1 Expression of synthetic L1 and L2 protein in undifferentiated cells. 15 Materials and Methods Codon replacements in the bovine PV (BPV) L1 and L2 genes The DNA and amino acid sequences of the wild-type L1 (SEQ ID NOS:1,2)and L2 genes (SEQ ID 20 NOS:5,6) are shown respectively in Figures 1A and lB. To determine whether the presence of rare codons in wild-type L1 (SEQ ID NO:l) and L2 (SEQ ID NO:5) genes (Table 1) inhibited translation, we synthesized the L1 (SEQ ID NO:3) and L2 (SEQ ID NO:7) genes by using 25 synonymous substitutions as shown. To construct the synthetic sequences, we synthesized 11 pairs of oligonucleotides for L1 and 10 pairs of oligonucleotides for L2. Each pair of oligonucleotides has restriction sites incorporated to 30 facilitate subsequent cloning (Figures 1A and 1B). The degenerate oligonucleotides were used to amplify SUBSTITUTE SHEET(RULE 26) WO 99/02694 42 PCT/AU98/00530 L1 and L2 sequences by PCR using a plasmid with BPV1 genome as the template. The amplified fragments were cut with appropriate enzymes and sequentially ligated to pUC18 vector, producing pUCHBL1 and pUCHBL2. The 5 synthetic L1 (SEQ ID NO:3) and L2 (SEQ ID NO:7) sequences were sequenced and found to be error-free, and then sub-cloned into the mammalian expression vector pCDNA3 containing SV40 ori (Invitrogen), giving expression plasmids pCDNA/HBL1 and pCDNA/HBL2. To 10 compare expression of L1 and L2 with that of the original sequences, the wild type L1 (SEQ ID NO:l) and L2 (SEQ ID NO:5) genes were cloned into the pCDNA3 vector, resulting in pCDNA/BPVLIwt and pCDNA/BPVL2wt. 15 Immunofluorescence and Western blot staining For immunoblotting assays, Cos-i cells in 6-well plates were transfected with 2 pg L1 or L2 expression plasmids using lipofectamine (Gibco). 36 20 hrs after transfection, cells were washed with 0.15M phosphate buffered 0.9% NaCI (PBS) and lysed in SDS loading buffer. The cellular proteins were separated by 10% SDS PAGE and blotted onto nitrocellulose membrane. The L1 or L2 proteins were identified by 25 electrochemiluminescence (Amersham, UK), using BPV1 L1 (DAKO) or L2-specific (17) antisera. For immunofluorescent staining, Cos-i cells were grown on 8-chamber slides, transfected with plasmids, and fixed and permeabilised with 85% ethanol 36hr after 30 transfection. The slides were blocked with 5% milk-PBS and probed with L1 or L2-specific antisera, followed by FITC-conjugated anti-rabbit IgG (Sigma). For GFP or SUBSTITUTE SHEET(RULE 26) WO 99/02694 43 PCT/AU98/00530 PGFP plasmid transfected cells, the cell were fixed with 4% buffered formaldehyde and viewed by epi fluorescence microscopy. 5 Northern blotting Cos cells transfected with various plasmids were used to extract cytoplasmic or total RNA using the QIAGEN RNeasy mini kit according to the supplier's handbook. Briefly, for cytoplasmic RNA 10 purification, buffer RLN (50 mM Tris, pH 8.0, 140 mM NaCI, 1.5 mM MgCl 2 and 0.5% NP40) was directly added to monolayer cells and cells were lysed in 4 °C for 5 min. After the nuclei were removed by centrifugation, cytoplasmic RNAs were purified by column. For total 15 RNA extraction, the monolayer cells were lysed using buffer RLT supplied by the kit and RNA was purified by spin column. The purified RNAs were separated by 1.5% agarose gel in the presence of formaldehyde. The RNAs were then blotted onto nylon membrane and probed with 20 (a) 1:1 mixed 5'-end labelled L1 wt and HBL1 fragments; (b) 1:1 mixed 5'-end labelled L2 wt and HBL2 fragments; (c) 1:1 mixed 5'end labelled GFP and PGFP fragments or (d) randomly labelled PAGDH fragment. The blots were washed extensively at 65 0 C 25 and exposed to X-ray films for three days. Results To test the hypothesis that the codon composition of the genes encoding the L1 and L2 capsid 30 proteins of papillomavirus (PV) contributes to their preferential expression in differentiated epithelial SUBSTITUTE SHEET (RULE 26) WO 99/02694 44 PCT/AU98/00530 cells, we produced synthetic BPV1 L1 (SEQ ID NO:3) and L2 (SEQ ID NO:7) genes, substituting codons preferentially used in mammalian genes for the codons frequently present in the wild type BPV1 L1 and L2 5 sequences which are rare in eukaryotic genes (Figures 1A, 1B). For the L1 gene, a total of 202 base substitutions were made in 196 codons, without changing the encoded amino acid sequence (Figure 1A). 10 This synthetic "humanized" BPV L1 gene (SEQ ID NO:3) was designated HBL1. In a similarly modified BPVl L2 gene (SEQ ID NO:7) designated HBL2, 303 bases were changed to substitute 290 less frequently used codons with the corresponding preferentially used codons. 15 Using the synthetic HBL1 (SEQ ID NO:3) and HBL2 (SEQ ID NO:7) genes, we constructed two eukaryotic expression plasmids based on pCDNA3, and designated pCDNA/HBL1 and pCDNA/HBL2. Similar expression plasmids, constructed with the wild type BPVl L1 (SEQ 20 ID NO:1) and BPVl L2 (SEQ ID NO:5) genes, were designated pCDNA/BPVLiwt and pCDNA/BPVL2wt, respectively. In each of these plasmids the SV40 ori allowed replication in Cos-i cells, and the L1 or L2 gene was driven by a strong constitutive CMV promoter. 25 To compare the expression of the synthetic humanized and the wild type BPV1 L1 or BPV1 L2 genes, we separately transfected Cos-1 cells with each of the L1 and L2 plasmids described above. Transfected cells were analyzed for expression of L1 (SEQ ID NO:2,4) or 30 L2 (SEQ ID NO:6,8) protein by immunofluorescence 36 hr after transfection (Figures 2A and 3A). Cells transfected with the pCDNA3 expression plasmid SUBSTITUTE SHEET (RULE 26) WO 99/02694 45 PCT/AU98/00530 containing the synthetic humanized L1 (SEQ ID NO:3) or L2 (SEQ ID NO:7) genes were observed to produce large amounts of the corresponding protein, while cells transfected with expression plasmids with the wild 5 type L1 (SEQ ID NO:l) or L2 (SEQ ID NO:5) sequences produced no detectable L1 or L2 protein (Figures 2A and 3A, see nuclear staining of L1 and L2 proteins). To compare more accurately the expression of the different L1 and L2 constructs, L1 and L2 protein 10 expression was assessed by immunoblot in Cos-1 cells transfected with the wild type or synthetic humanized BPV1 L1 or L2 pCDNA3 expression constructs (Figures 2B and 3B). Large amounts of immunoreactive L1 and L2 proteins were expressed from the synthetic humanized 15 L1 (SEQ ID NO:3) and L2 (SEQ ID NO:7) sequences, but no L1 or L2 protein was expressed from the wild type L1 and L2 sequences (SEQ ID NO:1,5). To establish whether the alterations to the primary sequence of the L1 and L2 mRNA which resulted 20 from the codon alterations also affected steady state expression of the corresponding message, mRNA was prepared from Cos-1 cells transfected with the various capsid protein gene constructs. Using GAPDH as an internal standard it was established by Northern blot 25 that two to three times more modified than wild type L1 mRNA, and similar levels of wild type and modified L2 mRNA were present in the cytoplasm of transfected cells (Figures 2C and 3C). The amount of L1 or L2 protein expressed per arbitrary unit of L1 or L2 mRNA 30 was at least 100 fold higher for the humanized gene constructs than for the natural gene constructs. SUBSTITUTE SHEET (RULE 26) WO 99/02694 46 PCT/AU98/00530 EXAMPLE 2 Papillomavirus late protein translation in vitro 5 Materials and Methods In vitro translation assay One microgram of each plasmid was incubated with 20 4Ci 35 S-methionine (Amersham) and 40 yL T7 coupled rabbit reticulocyte or wheat germ 10 lysates (Promega). Translation was performed at 30 oC and stopped by adding SDS loading buffer. The L1 proteins were separated by 10% SDS PAGE and examined by autoradiography. 15 Production of aminoacyl-tRNA 2.5 x 10 -4 M tRNA (Boehringer) was added to a 20 AL reaction containing 10 mM Tris-acetate, pH.7.8, 44 mM KC1, 12 mM MgC1 2 , 9 mM -mercaptoethanol, 38 mM ATP, 0.25 mM GTP and 7 iL rabbit reticulocyte 20 extract. The reaction was carried out at 25 OC for 20 min, and 30 iL H 2 0 was added to the reaction to dilute the tRNAs to 1 x 10 4 M. The aminoacyl-tRNAs were then aliquoted and stored at -70 oC. 25 Results As the major limitation to expression of the wild type BPV L1 and L2 genes appeared to be translational in our system we wished to test whether this limitation reflected a limited availability of 30 the appropriate tRNA species for gene translation. As transient expression of the synthetic genes within SUBSTITUTE SHEET(RULE 26) WO 99/02694 47 PCT/AU98/00530 intact cells may be regulated by many factors, we tested our hypothesis in a cell free system using rabbit reticulocyte lysate (RRL) or wheat germ lysate to examine gene translation. Similar amounts of 5 plasmids expressing the wild type or synthetic humanized BPV1 L1 gene were added to a T7-DNA polymerase coupled RRL transcription/translation system in the presence of "S-methionine. After 20 minutes, translated proteins were separated by SDS 10 PAGE and visualized by autoradiography. Efficient translation of the modified L1 gene was observed (Figure 4, top panel, lane 2), while translation of the wild type BPV1 L1 sequence resulted in a weak 55 kDa L1 band (Figure 4, upper panel, lane 1). We 15 reasoned that although the wild type sequence was not optimized for translation in RRL, some translation would occur as there would be no cellular mRNA species competing for the 'rare' codons present in the wild type L1 sequence. The above data suggest that the 20 observed difference in efficiency of translation of the wild type and synthetic humanized L1 genes is a consequence of limited availability of the tRNAs required for translation of the rare codons present in the wild type gene. We therefore expected that 25 addition of excess tRNA to the in vitro translation system would overcome the inhibition of translation of the wild type L1 gene. To address this question, 10 - 5 M aminoacyl-tRNAs from yeast were added into the RRL translation system, and L1 protein synthesis was 30 assessed. Introduction of exogenous tRNAs resulted in a dramatic improvement in translation of the wild type L1 sequence, which now gave a yield of L1 protein SUBSTITUTE SHEET(RULE 26) WO 99/02694 48 PCT/AU98/00530 comparable to that observed with the synthetic humanized L1 sequence (SEQ ID NO:3) (Figure 4, top panel). Enhancement of translation of the wild type L1 gene (SEQ ID NO:l) by aminoacyl-tRNA was dose 5 dependent, with an optimum efficiency at 10 - M tRNA. As addition of exogenous tRNA improved the yield of L1 protein translated from the wild type L1 gene sequence (SEQ ID NO:l), we assessed the speed of translation of wild type and humanized L1 mRNA. Samples were 10 collected from the translation mixture every 2 minutes, starting at the 8th minute. Translation of L1 (SEQ ID NO:2,4) from the wild type sequence (SEQ ID NO:l) was much slower than from the humanized L1 sequence (SEQ ID NO:3) (Figure 4 bottom panel), and 15 the retardation of translation could be completely overcome by adding exogenous tRNA from commercially available yeast tRNA. Yeast tRNA was chosen in the above analysis because the codon usage in yeast is similar to that of papillomavirus (Table 1). Addition 20 of exogenous tRNA did not significantly improve the translation of the humanized L1 gene (SEQ ID NO:3), indicating that this sequence was optimized with regard to codon usage for the rabbit reticulocyte translation machinery (Figure 4, bottom panel). In 25 separate experiments we established that wt L1 translation could also be enhanced by liver tRNA (Figure 4), and by tRNAs extracted from bovine skin epidermis, which presumably constitutes a mixture of tRNAs from differentiated and undifferentiated cells 30 (data not shown). SUBSTITUTE SHEET(RULE 26) WO 99/02694 49 PCT/AU98/00530 EXAMPLE 3 Translation of wild type L1 is efficient in wheat germ 5 extract. To further test our hypothesis that tRNA availability is a determinant of expression of the wild type BPV1 L1 gene (SEQ ID NO:l), we examined the translation of L1 in a cell type in which a quite 10 different set of tRNAs would be available. In a wheat germ translation system, wild type L1 mRNA was translated as efficiently as humanized L1 mRNA, and addition of exogenous aminoacyl-tRNAs did not improve the translation efficiency of either wild type or 15 humanized sequences (Figure 4 bottom panel). This indicated that in wheat germ there are sufficient of the tRNAs which are limiting for translation of wild type L1 sequence in RRL to allow efficient L1 translation. 20 EXAMPLE 4 Modified late genes can be expressed in undifferentiated cells from papillomavirus promoter(s) 25 While our data presented above indicates that translation is limiting for the production of BPV1 capsid proteins in our test system, these experiments were conducted in systems which are not truly representative of the viral late gene 30 transcription from the BPV genome, in part because the genes were driven by a strong CMV promoter. We therefore wished to establish whether synthetic SUBSTITUTE SHEET(RULE 26) WO 99/02694 50 PCT/AU98/00530 humanized BPV capsid protein mRNA would be translated more efficiently than the wild type mRNA, if transcribed from the natural BPV1 promoter. This would establish whether translation was indeed one of 5 the limiting factors for expression of BPV1 late genes driven from the natural cryptic late gene promoter in an undifferentiated cell. The BPV genome was cleaved at nt 4450 and 6958 with BamHI/HindIII and the original L1 (nt 4186-5595) and L2 (5068-7095) ORFs 10 were removed. The synthetic humanized L2 gene (SEQ ID NO:7), together with an SV40 ori sequence to allow plasmid replication in eukaryotic cells, were inserted into the BPV genome lacking Ll/L2 ORF sequences. This plasmid (Figure 5A) was designated pCICR1. A similar 15 plasmid was constructed with wild type (SEQ ID NO:5) rather than synthetic humanized L2 and designated pCICR2. Cos-1 cells were transfected with these plasmids and L2 protein expression examined by immunofluorescence of transfected cells. Synthetic 20 humanized L2 (SEQ ID NO:7), driven by the natural BPV 1 promoter, was efficiently expressed, whereas the wild type L2 sequence (SEQ ID NO:5), driven from a similar construct, produced no immunoreactive L2 protein (SEQ ID NO:6,8) (Figure 5B). As 25 undifferentiated cells supported the expression of the humanized L2 gene (SEQ ID NO:7) but not the wild type L2 (SEQ ID NO:5) expressed from the cryptic late BPV promoter, the results confirmed our earlier observations from experiments using the CMV promoter. 30 However, the plasmids tested here contained SV40 ori, designed to replicate the DNA in Cos cells. The increased copy number of the BPV1 L2 plasmids or the SUBSTITUTE SHEET(RULE 26) WO 99/02694 51 PCT/AU98/00530 transcriptional enhancing activity of the SV40 ori might explain in part the increased efficiency of expression of L2 in this experimental system when compared with infected skin. However, the marked 5 difference in expression between the natural and humanized genes seen with a CMV promoter construct is still observed with the natural promoter. EXAMPLE 5 10 Substitution of papillomavirus-preferred codons prevents translation but not transcription of a non papillomavirus gene in undifferentiated cells. Materials and Methods 15 Codon replacement in gfp gene To construct a modified gfp gene (SEQ ID NO:11) using papillomavirus preferred codons (PGFP), 6 pairs of oligonucleotides were synthesized. Each pair of oligonucleotides has restriction sites incorporated 20 and was used to amplify gfp using a humanized gfp gene (SEQ ID NO:9) (GIBCO) as template. The PCR fragments were ligated into the pUC18 vector to produce pUCPGFP. The PGFP gene was sequenced, and cloned into BamHI site of the same mammalian expression vector, pCDNA3, 25 under the CMV promoter. The DNA and deduced amino acid sequences of the humanized GFP gene are shown in Figures lC. Mutations introduced into the wild type gfp gene (SEQ ID NO:9) to produce the Pgfp gene (SEQ ID NO:11) are indicated above the corresponding 30 nucleotides of the wild-type sequence. SUBSTITUTE SHEET (RULE 26) WO 99/02694 52 PCT/AU98/00530 Results To further confirm that codon usage can alter gene expression in mammalian cells, we made a further variant on a synthetic gfp gene modified for 5 optimal expression in eukaryotic cells (Zolotukhin, et al., 1996. J. Virol. 70:4646-4654). In our variant, codons optimized for expression in eukaryotic cells were substituted by those preferentially used in papillomavirus late genes. Of 240 codons in the 10 humanized gfp gene (SEQ ID NO:9), which expresses high levels of fluorescent protein in cultured cells, 156 were changed to the corresponding papillomavirus late gene-preferred codons to produce a new gfp gene (SEQ ID NO:11) designated Pgfp. Expression of Pgfp (SEQ ID 15 NO:11) in undifferentiated cells was compared with that of humanized gfp (SEQ ID NO:9). Cos-1 cells transfected with the humanized gfp (SEQ ID NO:9) produced a bright fluorescent signal after 24 hrs, while cells transfected with Pgfp (SEQ ID NO:11) 20 produced only a faint fluorescent signal (Figure 6A). To confirm that this difference reflected differing translational efficacy, gfp specific mRNA was tested in both transfections and found not to be significantly different (Figure 6B.). Thus, codon 25 usage and corresponding tRNA availability apparently determines the observed restriction of expression of PV late genes, and modification of codon usage in other genes similarly prevents their expression in undifferentiated cells. SUBSTITUTE SHEET (RULE 26) WO 99/02694 53 PCT/AU98/00530 EXAMPLE 6 PGFP with papillomavirus-preferred codons is 5 efficiently expressed in vivo in differentiated mouse keratinocytes. Materials and Methods Delivery of plasmid DNA into mouse skin by gene gun 10 Fifty microgram of DNA was coated onto 25 pg gold micro-carriers by calcium precipitation, following the manufacturer's instructions (Bio-Rad). C57/bl mouse skin was bombarded with gold particles coated with DNA plasmid at a pressure of 600 psi. 15 Serial sections were taken from the skin and examined for distribution of the particles, confirming that a pressure of 600 psi could deliver particles throughout the epidermis. Results 20 Mice were shot with gold beads carrying PGFP DNA plasmid and, 24 hrs later, skin samples were cut from the site of DNA delivery and examined for expression of GFP protein (SEQ ID NO:10,12). Fluorescence was detected mostly in upper keratinocyte 25 layers, representing the differentiated epithelium, and was not seen in undifferentiated basal cells. In contrast, skin sections shot with the humanized GFP plasmid showed fluorescence in cells randomly distributed throughout the whole epidermis (Figure 7). 30 Although GFP-positive cells were rare in both PGFP (SEQ ID NO:11) and GFP-inoculated (SEQ ID NO:9) mouse SUBSTITUTE SHEET (RULE 26) WO 99/02694 54 PCT/AU98/00530 skin, fluorescence was observed only in differentiated strata in the PGFP sample (SEQ ID NO:11), whereas fluorescence was observed throughout the epidermis in GFP-inoculated (SEQ ID NO:9) mouse skin. This result 5 confirmed that the use of papillomavirus-preferred codons resulted in the protein being expressed in an epithelial differentiation-dependent manner. EXAMPLE 7 10 Microinjection of yeast tRNA and wild type L1 gene into cultured cells To test if yeast tRNA could facilitate expression of wild type BPV-1 L1 (SEQ ID NO:l) (as 15 yeast uses a similar set of codons to those observed in papillomavirus for its own genes), 2 pL of mixtures containing tRNA (2 mg/mL) (purified yeast tRNA (Boehringer Mannheim) or bovine liver tRNA - control) and BPV L1 DNA (2 Ag/mL) can be injected into CV-1 20 cells (Lu and Campisi, 1992, Proc. Natl. Acad. Sci. U. S. A. 89 3889-3893). The injected cells can then be cultured for 48 hrs at 37 OC and examined for expression of L1 gene by standard immunofluoresence methods using BPV Ll-specific antibody and quantified 25 by FACS analysis (Qi et al 1996, Virology 216 35-45). EXAMPLE 8 Establishment of a cell line which can 30 continuously produce HPV virus particles To produce infectious PV, various methods have been tried including the epithelial raft culture SUBSTITUTE SHEET(RULE 26) WO 99/02694 55 PCT/AU98/00530 system (Dollard et al 1992, Genes Dev 6 1131-1142), and cell lines containing BPV-1 episomal DNA, and infected by BPV-1 Ll/L2 recombinant vaccinia (Zhou et al 1993, J. Gen. Virol. 74 763-768) or transfected by 5 SFV RNA (Roden et al 1996, J. Virol. 70 5875-5883). The yield of particles is in each case low. In a reduction to practice of our discovery, synthetic BPV L1 (SEQ ID NO:3) and L2 genes (SEQ ID NO:7) (as described in Example 1) can be used to produce 10 infectious BPV in a cell line containing BPV-1 episomal DNA. Fibroblast cell lines (CON/BPV) containing BPV-1 episomal DNA (Zhou et al 1993, J. Gen. Virol. 74 763-768) can be used for transfection of the synthetic BPV-1 L1 (SEQ ID NO:3) and L2 genes 15 (SEQ ID NO:7) under control of CMV promoter. BPV particles may then be purified from the cell lysate and the purified particles examined for the presence of BPV-1 genome. Standard methods such as transfection with lipofectamine (BRL) and G418 20 selection of transfected cells can be utilized to generate suitable transfectants expressing humanized L1 (SEQ ID NO:3) and L2 (SEQ ID NO:7) in the background of BPV-1 episomal DNA. Examination of L1 and L2 protein expression can be performed using 25 rabbit anti-BPV L1 or rabbit anti-BPV L2 polyclonal antibodies. BPV particles can then be purified using our published methods (Zhou et al 1995, Virology 214 167-176) and can be characterized by electron microscopy and DNA blotting. The infectivity of BPV 30 particles isolated from the cultured cells may be tested in focus formation assays using C127 fibroblasts. SUBSTITUTE SHEET(RULE 26) WO 99/02694 56 PCT/AU98/00530 EXAMPLE 9 Method for extracting and measuring tRNA from tissues Tissue(100g) is homogenized in a Waring 5 Blender with 150 mL of phenol (Mallinckrodt, Analytical Reagent, 88%) saturated with water (15:3) and 150 mL of 1.0 M NaCI, 0.005 M EDTA in 0.1 M Tris chloride buffer, pH 7.5. The homogenate was spun for ten minutes at top speed in the International 10 clinical centrifuge and the upper layer was carefully decanted off. To this aqueous layer, three volumes of 95% ethanol were added. The resultant precipitate was spun down at top speed in the International clinical centrifuge and resuspended in 250 mL of 0.1 M 15 Tris/chloride buffer, pH 7.5. This solution was added (flow rate of 15-20 drops per minute) to a column (2 x 10 cm) of 2 g of DEAE-cellulose previously equilibrated with cold 0.1 M Tris-chloride buffer pH 7.5. The column was then washed with 1 L of Tris 20 chloride buffer, pH 7.5 and the RNA eluted with 1.0 M NaCl in 0.1 M Tris-chloride buffer, pH 7.5. The first 10 mL of NaCl solution were discarded as "hold-up." Sufficient salt solution (60-80 mL) was then collected until the optical density of the effluent was less 25 than three at 260 nm. This solution was extracted twice with an equal volume of phenol saturated with water and twice with ether. To the aqueous solution containing the RNA, three volumes of 95% ethanol were added and the solution wag allowed to stand overnight 30 in the cold. The precipitate was spun down and washed first with 80% and then twice with 95% ethanol and SUBSTITUTE SHEET(RULE 26) WO99/02694 57 PCT/AU98/00530 dried in a vacuum. Approximately 60 mg of soluble RNA were obtained from a 100-g lot of rat liver. Quantitating tRNAs 5 The following nylon membranes are used: Biodine A and B (PALL). For the preparation of dot blots, the tRNA samples (from 1 pg to 5 ng) are denatured at 60 oC for 15 min in 1-5 pL of 15% formaldehyde. 10x SSC (SSC is NaCl 0.3 M, tri-sodium 10 citrate 0.03 M). The samples are spotted in 1 pL aliquots onto the membranes that have been soaked for 15 min in deionized water and slightly dried between two sheets of 3MM Whatman paper prior to the application of the samples. The tRNAs are fixed 15 covalently (in the membranes by ultraviolet irradiation (10 mm using an ultraviolet lamp at 254 nm and 100 W strength at a distance of 20 cm) and the membranes are baked for 2-3 h at 80 OC. A 5' end labelled synthetic deoxyribo 20 oligonucleotide complementary to the A54-A73 sequence of the tRNA is used as a probe for the hybridization experiments. Labelling of the oligonucleotide is performed by direct phosphorylation of the 5' OH' ended probe. 25 For hybridisation experiments, the UV irradiated membranes are first preincubated for 5 h at 50 C in 50% deionized formamide, 5 x SSC, 1% SDS, 0.04% Ficoll 0.04% polyvinylpyrrolidone and 250 AL/mL of sonicated salmon sperm DNA using 5 mL of buffer for 30 100 cm 2 of membrane. Hybridization is finally performed overnight at 50 OC in the above solution (2.5 mL/100 cm 2 ) where the labeled probe has been SUBSTITUTE SHEET (RULE 26) WO 99/02694 58 PCT/AU98/00530 added. After hybridization, the membranes are washed twice in 2 x SSC, 0.1% SDS for 5 min at room temperature, twice in 2 x SSC, 1% SDS for 30 mm at 60 oC and finally in 0.1 x SSC. 0.1% SDS for 30 min at 5 room temperature. To detect the hybridized probes the membranes are exposed for 16 h to Fuji XR film at 70 OC with an intensifying screen. Sequence of tRNA probes 10 The sequences of the tRNA probes are as follows: AlaCA: 5'-TAAGGACTGTAAGACTT (SEQ ID NO:13) ArgGA: 5'-CGAGCCAGCCAGGAGTC (SEQ ID NO:14) Asn A c : 5'-CTAGATTGGCAGGAATT (SEQ ID NO:15) 15 AspGAc: 5' -TAAGATATATAGATTAT (SEQ ID NO:16) CsyGC: 5'-AAGTCTTAGTAGAGATT (SEQ ID NO:17) GluGA: 5'-TATTTCTACACAGCATT (SEQ ID NO:18) Glno: 5'-CTAGGACAATAGGAATT (SEQ ID NO:19) Glyya : 5'-TACTCTCTTCTGGGTTT (SEQ ID NO:20) 20 HisCAC: 5'-TGCCGTGACTCGGATTC (SEQ ID NO:21) IleATC: 5'-TAGAAATAAGAGGGCTT (SEQ ID NO:22) LeuCTA: 5'-TACTTTTATTTGGATTT (SEQ ID NO:23) Leu cTT : 5' -TATTAGGGAGAGGATTT (SEQ ID NO:24) LysA": 5'-TCACTATGGAGATTTTA (SEQ ID NO:25) 25 Lys"A: 5'-CGCCCAACGTGGGGCTC (SEQ ID NO:26) Metelong 5'-TAGTACGGGAAGGATTT (SEQ ID NO:27) PheTTc: 5'-TGTTTATGGGATACAAT (SEQ ID NO:28) ProCCA : 5' -TCAAGAAGAAGGAGCTA (SEQ ID NO : 29) Procc: 5'-GGGCTCGTCCGGGATTT (SEQ ID NO:30) 30 Ser A G C: 5' -ATAAGAAAGGAAGATCG (SEQ ID NO:31) ThrAA: 5'-TGTCTTGAGAAGAGAAG (SEQ ID NO:32) TyrTAC : 5'-TGGTAAAAAGAGGATTT (SEQ ID NO:33) SUBSTITUTE SHEET (RULE 26) WO 99/02694 59 PCT/AU98/00530 ValGTA: 5'-TCAGAGTGTTCATTGGT (SEQ ID NO:34) EXAMPLE 10 5 Comparison of the relative abundance of tRNA species in undifferentiated and differentiated keratinocytes Materials and Methods Isolation of epidermal cells 2-day old mice were killed and their skins 10 removed. The skins were digested with 0.25% trypsin PBS at 4 OC overnight. The epidermis was separated from the dermis using forceps and minced with scissors in 10% FCS DMEM medium. The cell suspension was first filtered through a 1 mm and then a 0.2 mm nylon net. 15 The cell suspension was then pelleted and washed twice with PBS. Density gradient centrifugation The keratinocytes were resuspended in 30% 20 Percoll and separated by centrifugation through a discontinuous Percoll gradient (1.085, 1.075 and 1.050 g/mL) at 1200 x g at room temperature for 25 min. The cells were then washed with PBS and used to extract tRNA. 25 tRNA purification The cells were lysed in 5 mL of lysis buffer (0.2 M NaOH, 1% SDS) for 10 min at room temperature. The lysate was neutralized with 5 mL of 30 3.0 M potassium acetate (pH 5.5). After centrifugation, the supernatant was diluted with 3 SUBSTITUTE SHEET(RULE 26) WO 99/02694 60 PCT/AU98/00530 volumes of 100 mM Tris (pH 7.5) and added to a DEAE column equilibrated with 100 mM Tris (pH 7.5). An equal volume of isopropanol was added to the aqueous solution containing tRNA, and the solution was allowed 5 to stand overnight at 4 oC. The tRNA was spun down and washed with 75% ethanol, then dissolved in RNase free water. tRNA blotting 10 10 ng of each tRNA sample in 1 AL was denatured in 60 0 C for 15 min in 4 JL formaldehyde and 5 AL 20 x SSC. The samples were spotted in 1 pL aliquots onto charged nylon membrane (Amersham), and the tRNAs were fixed with UV and probed with 2

P

15 oligonucleotides. Results Comparison of the abundance of the tRNA species in undifferentiated and differentiated keratinocytes showed that the levels of some tRNA 20 populations changed dramatically. For example, the levels of tRNAs specific for AlaGCA, LeuCTT, LeuCTA were increased in differentiated cells while tRNAs for ArgCGA, ProccI, AsnAAG were more abundant in undifferentiated keratinocytes (see Table 2). 25 GENERAL DISCUSSION In the present specification the inventors have confirmed that one determinant of the efficiency 30 of translation of a gene in mammalian cells is its codon composition. This observation has commonly been SUBSTITUTE SHEET(RULE 26) WO 99/02694 61 PCT/AU98/00530 made when genes from prokaryotic organisms have been expressed in eukaryotic cells (Smith, D. W., 1996, Biotechnol. Prog. 12:417-422). The present inventors have also presented evidence that mRNA encoding the 5 capsid genes of papillomavirus are not effectively translated in cultured eukaryotic cells, apparently because tRNA availability is rate limiting for translation, and that the block to PV late gene translation in eukaryotic cells in culture can be 10 overcome by altering the codon usage of the late genes to match the consensus for mammalian genes, or alternatively by providing exogenous tRNAs. Alterations to mRNA secondary structure or protein binding (Sokolowski, et al., 1998, J. Virol. 72:1504 15 1515) as a consequence of the changes to the primary sequence of the PV capsid genes might contribute to the observed differences in efficiency of translation of the natural and modified PV capsid gene mRNAs in cultured cells. However, the enhancement of 20 translation of the natural but not the modified mRNA that was observed after addition of tRNA in a mammalian in vitro translation system, which was not observed in a plant translation system, strengthens the argument that tRNA availability is rate limiting 25 for translation of the natural gene in mammalian cells. A shortage of critical tRNAs could result in slowed elongation of the nascent peptide or premature termination of translation (Oba, et al., 1991, Biochimie 73:1109-1112). Slowed elongation appears to 30 be the major consequence for the PV late gene. Analysis of codon usage in the PV genome shows that PV late genes use many codons that mammalian cells rarely SUBSTITUTE SHEET(RULE 26) WO 99/02694 62 PCT/AU98/00530 use. For example, PV frequently uses UUA for leucine, CGU for arginine, ACA for threonine, and AUA for isoleucine, whereas these codons are significantly less often used in mammalian genes. In contrast, 5 papillomavirus late genes can be expressed efficiently in yeast (Jansen, et al., 1995, Vaccine 13:1509-1514) (Sasagawa, et al., 1995, Virology 206:126-135) and the codon composition of yeast and papillomavirus genes are similar (Table 1). An apparent exception is that 10 PV L1 genes can be efficiently expressed in insect cells (Kirnbauer, et al., 1992, Proc. Natl. Acad. Sci. USA 89:12180-12184) using recombinant baculovirus, or in various undifferentiated mammalian cells using recombinant vaccinia (Zhou, et al., 1991, Virology 15 185:251-257). As infection with vaccinia or baculovirus down regulates cellular protein synthesis, the efficient expression of the L1 capsid proteins under these circumstances may occur because less cellular mRNA is available in a virus infected cell to 20 compete with the L1 mRNA for the rarer tRNAs. Codon composition could be a more general determinant of gene expression within different stages of differentiation of the same tissue. Although the genetic code is essentially universal, different 25 organisms show differences in codon composition of their genes, while the codon composition of genes tends to be relatively similar for all genes within each organism, and matched to the population of iso tRNAs for that organism (Ikemura, T., 1981, J. Mol. 30 Biol. 146:1-21). However, populations of tRNAs in differentiating and neoplastic cells are different (Kanduc, D., 1997, Arch. Biochem. Biophys. 342:1-6; SUBSTITUTE SHEET(RULE 26) WO 99/02694 63 PCT/AU98/00530 Yang, and Comb, 1968, J. Mol. Biol. 31:138-142; Yang, and Novelli, 1968, Biochem. Biophys. Res. Commun. 31: 534-539) and the tRNA populations also vary in cells growing under different growth conditions (Doi, et 5 al., 1968, J. Biol. Chem. 243:945-951). Accordingly, the inventors believe that codon composition and tRNA availability together provide a primitive mechanism for spatial and/or temporal regulation of gene expression. It is well recognized that the G+C 10 content of many dsDNA viruses, a crude marker for viral gene codon composition, is markedly different from the G+C content of the DNA of the cells they infect (Strauss, et al., 1995, "Virus Evolution" in Virology (eds. Fields, B. N., et al.), Lipipincott 15 Raven, Philadelphia, pp 153-171). Viruses may therefore have evolved to take advantage of codon composition to regulate their own program of gene expression, perhaps to avoid expression of lethal quantities of viral proteins in undifferentiated cells 20 where the virus utilizes the cellular machinery to replicate its genome. As the inventors' observations represent an apparently novel mechanism of regulation of gene translation within a single tissue, it is relevant to 25 consider how this relates to previously proposed hypotheses for the restriction of expression of PV late genes to differentiated epithelium. A number of explanations have been proposed for the observation that PV late genes are only effectively expressed in 30 differentiated epithelium. Reduced late gene transcription may reflect dependence of transcription from the late promoter on transcription factors SUBSTITUTE SHEET(RULE 26) WO 99/02694 64 PCT/AU98/00530 expressed only in differentiated epithelium, or may alternatively be due to suppression of late promoter transcription by viral (Stubenrauch, et al., 1996, J. Virol. 70:119-126) or cellular gene products expressed 5 in undifferentiated cells. The "late" promoters of HPV31b and of HPV5 (Haller, et al., 1995, Virology 214:245-255; Hummel, et al., 1992, J. Virol. 66:6070 6080) are described as differentiation dependent, although the search for relevant transcription control 10 factors in differentiated keratinocytes by conventional footprinting and DNA binding studies has to date been unrewarding. Our data show that capsid proteins are not translated from PV L1 and L2 mRNAs in cells transfected with CMV promoter-based expression 15 vectors (Fig. 2), suggesting that in addition to any transcriptional controls that may exist that there is a post-transcriptional block to capsid protein synthesis in undifferentiated cells. Sequences resembling 5' splice donor sites exist within L1 or L2 20 mRNA or within flanking untranslated message which are inhibitory to transcription of genes with which they are associated (Kennedy, et al., 1991, J. Virol. 65:2093-2097) (Furth, et al., 1994, Mol. Cell. Biol. 14:5278-5289). Other AU rich sequences in L1 or L2 25 mRNA promote mRNA degradation (Sokolowski, et al., 1997, Oncogene 15:2303-2319). These mechanisms inhibiting L1 and L2 expression in undifferentiated cells have yet to be shown to be inactive in differentiated epithelium, to explain the successful 30 translation of late genes in this tissue. Because inhibitory RNA sequences within the L1 coding sequence could have been rendered non SUBSTITUTE SHEET(RULE 26) WO 99/02694 65 PCT/AU98/00530 functional by the systematic codon substitution employed in the experiments described herein and the untranslated inhibitory sequences were not included in the inventors' test system, the respective roles of 5 inhibitory sequences and codon mismatch in suppression of PV late gene expression in cultured mammalian cells cannot be determined. However, regulatory sequences promoting RNA degradation or inhibiting translation are presumed to act through interaction with nuclear 10 or cytoplasmic proteins (Sokolowski, et al., 1998, J. Virol. 72:1504-1515), and inefficient translation of native sequence L1 mRNA was observed in a cell free translation system from anucleate cells, demonstrating that codon composition of the PV late genes must play 15 some role in regulation of PV late gene translation. Further evidence supporting the hypothesis that codon composition is an important determinant of PV capsid gene expression was gathered from an analysis of the 84 PV L1 sequences currently available 20 in Genebank. The codon composition of the L1 genes, and particularly the frequency of usage of the rarer codons, was essentially the same across all the published sequences (data not shown) as would be predicted by the similar G+C content of the 25 papillomavirus genomes. The PV L1 gene is relatively conserved at the amino acid level, showing 60 - 80% amino acid homology between PV genotypes, as might be expected by the constraints on capsid protein function. There are, however, no obvious constraining 30 influences on the codon composition of the PV late genes beyond those of the inventors' hypothesis, as the late gene region does not code for other genes, SUBSTITUTE SHEET (RULE 26) WO 99/02694 66 PCT/AU98/00530 either in other reading frames or on the complementary DNA strand, and has no known cis acting regulatory functions. If codon composition of the capsid genes were not important for PV function, a considerable 5 heterogeneity of codon usage might therefore be expected, given the evolutionary diversity of PVs (Chan, et al. 1995, J. Virol. 69:3074-3083). Taken together, the data and evidence outlined herein makes a strong case that codon usage 10 is a significant determinant of expression of PV late genes in undifferentiated and differentiated epithelial cells, and that this observation is generalizable. The relative role of message instability and codon mismatch in determining 15 expression in differentiated tissues will require comparisons of transcriptional activity and translation of the L1 or L2 genes driven from strong constitutive promoters in differentiated and undifferentiated epithelium. Such work should now be 20 feasible using either transgenic technology or keratinocyte raft cultures. Although mechanisms of transcriptional regulation of PV L1 or L2 gene expression in the superficial layer of differentiated epithelium have 25 been proposed (Zeltner et al., 1994, J. Virol. 68:3620; Brown, et al., 1995, Virology 214:259; Stoler et al., 1992, Hum. Pathol. 23:117; Hummel et al., 1995, J. Virol. 69:3381; Haller et al., 1995, Virology 214:245; Barksdale and Baker, 1993, J. Virol. 30 67:5605), measurable PV late gene mRNA is not always associated with production of late proteins (Zeltner et al., 1994, supra; Ozbun and Meyers, 1997, J. Virol. SUBSTITUTE SHEET(RULE 26) WO 99/02694 67 PCT/AU98/00530 71:5161), and the data presented here suggest that translation regulation may play a major part in controlling PV late gene expression. This observation has implications as herein described for the 5 regulation of expression of genes related to the specialised functions of any differentiated tissue, and also for targeting of expression of therapeutic genes to such tissue while avoiding the potentially deleterious consequences of expression of the 10 exogenous gene in a self renewing stem cell population. The present invention has been described in terms of particular embodiments found or proposed by the present inventors to comprise preferred modes for 15 the practice of the invention. Those of skill in the art will appreciate that, in light of the present disclosure, numerous modifications and changes may be made in the particular embodiments exemplified without departing from the scope of the invention. All such 20 modifications are intended to be included within the scope of the appended claims. SUBSTITUTE SHEET(RULE 26) WO 99/02694 68 PCT/AU98/00530 TABLE LEGENDS TABLE 1 The codon usage data for human, cow yeast and wheat proteins are derived from published 5 results(18). The BPV1 data are from the sequences in the Genbank database. TABLE 2 Each iso-acceptor tRNA with anticodon shown 10 as superscript are shown on top row. The "+" indicates the abundance of tRNA wherein each "+" indicates about 10 fold increase. SUBSTITUTE SHEET(RULE 26) WO 99/02694 6 9 PCT/AU98/00530 TABLES TABLE 1 Frequency (per one thousand) of codon usage for individual organisms. Amino Codons Human Cow Yeast Wheat BPVL1/ acids L2 ARG CGA 5.4 5.5 2.3 2.3 7.2 CGC 11.3 12.2 2.0 7.5 4.1 CGG 10.4 11.2 1.1 4.6 5.1 CGU 4.7 3.7 7.5 1.1 10.4 AGA 9.9 9.9 24.0 4.1 14.4 AGG 11.1 11.4 7.5 7.1 9.3 LEU CUA 6.2 4.9 11.8 12.1 18.6 CUC 19.9 21.2 4.1 18.6 6.2 CUG 42.5 46.6 8.3 15.5 15.5 CUU 10.7 10.6 9.6 6.5 20.7 UUA 5.3 4.0 24.5 1.8 14.5 UUG 11.0 9.6 32.1 15.3 15.5 SER UCA 9.3 7.6 15.6 14.6 16.6 UCC 17.7 17.6 14.4 10.1 11.4 UCG 4.2 4.5 6.5 9.6 6.2 UCU 13.2 11.2 24.6 14.8 15.5 AGC 18.7 18.7 7.1 12.8 12.4 AGU 9.4 8.6 11.7 12.9 21.7 THR ACA 14.4 11.4 15.6 4.6 37.3 ACC 23.0 21.1 13.9 15.9 19.7 ACG 6.7 7.8 6.7 4.5 4.1 ACU 12.7 9.6 22.0 11.8 28.0 SUBSTITUTE SHEET (RULE 26) WO 99/02694 70 PCT/AU98/00530 Amino Codons Human Cow Yeast Wheat BPVL1/ acids L2 PRO CCA 14.6 12.0 21.4 71.2 22.8 CCC 20.0 19.2 5.9 11.1 15.5 CCG 6.5 7.9 4.1 19.4 0.0 CCU 15.5 14.6 12.8 10.3 33.1 ALA GCA 14.0 13.1 15.3 11.2 33.1 GCC 29.1 35.8 15.5 19.5 17.6 GCG 7.2 9.3 5.1 13.8 4.1 GCU 19.6 19.1 28.3 9.6 13.5 GLY GGA 17.1 16.2 8.9 25.9 22.8 GGC 25.4 28.1 8.9 28.0 12.4 GGG 17.3 19.2 5.1 28.5 22.8 GGU 11.2 11.8 34.9 9.6 18.6 VAL GUA 5.9 5.1 10.0 4.4 15.5 GUC 16.3 18.4 14.9 14.8 6.2 GUG 30.9 32.9 9.5 12.9 23.8 GUU 10.4 9.9 26.6 11.6 16.6 LYS AAA 22.2 21.6 37.7 4.5 37.2 AAG 34.9 37.1 35.2 17.4 13.5 ASN AAC 22.6 22.4 25.8 14.2 10.3 AAU 16.6 12.5 31.4 6.7 24.8 GLN CAA 11.1 9.7 29.8 171.8 22.8 CAG 33.6 34.4 10.4 79.4 17.6 HIS CAC 14.2 14.0 8.2 8.2 6.2 CAU 9.3 7.5 12.3 7.1 13.4 GLU GAA 26.8 24.4 48.9 7.8 36.2 GAG 41.4 45.4 16.9 19.7 21.7 ASP GAC 29.0 31.5 22.3 13.0 18.6 GAU 21.7 19.2 37.0 4.0 33.1 SUBSTITUTE SHEET (RULE 26) WO 99/02694 71 PCT/AU98/00530 Amino Codons Human Cow Yeast Wheat BPVL1/ acids L2 TYR UAC 18.8 20.3 16.5 24.5 17.6 UAU 12.5 10.5 16.5 12.5 18.6 CYS UGC 14.5 13.9 3.7 14.8 5.2 UGU 9.9 9.4 7.6 4.9 5.2 PHE UUC 22.6 25.5 20.0 14.1 7.2 UUU 15.8 17.0 23.2 15.0 23.8 ILE AUA 5.8 5.2 12.8 5.4 22.7 AUC 24.3 25.8 18.4 19.7 8.2 AUU 14.9 13.1 31.1 10.7 20.7 SUBSTITUTE SHEET (RULE 26) WO 99/02694 72 PCT/AU98/00530 TABLE 2 tRNA population changes as KC starts to differentiate. tRNA ArgcGA AlaGCA HisAc LeucTT LeuCTA Lys LysAAA Met I n i ProccI Supra + +++ + +++ +++ ++ + + + Basal +++ + ++ + + + + ++ +++ tRNA ValGTA ValGTI HiscAc AsnAAG ThrACA MetEl GlyWA Supra ++ + ++ + + + + Basal + + + +++ + ++ + SUBSTITUTE SHEET (RULE 26)

Claims (25)

1. A synthetic nucleic acid sequence capable of selectively expressing a protein in a target cell 5 or tissue of a mammal, wherein said selective expression is effected by replacing at least one existing codon of a parent nucleic acid sequence with a synonymous codon to form said synthetic nucleic acid sequence. 10

2. The nucleic acid sequence of claim 1, wherein said synonymous codon corresponds to an iso tRNA which, when compared to an iso-tRNA corresponding to the at least one existing codon, is in higher abundance in the target cell or tissue relative to one 15 or more other cells or tissues of the mammal.

3. The nucleic acid sequence of claim 1, wherein said synonymous codon corresponds to an iso tRNA which, when compared to an iso-tRNA corresponding to the at least one existing codon, is in higher 20 abundance in the target cell or tissue relative to a precursor cell or tissue.

4. The nucleic acid sequence of claim 1, wherein said synonymous codon corresponds to an iso tRNA which, when compared to an iso-tRNA corresponding 25 to the at least one existing codon, is in higher abundance in the target cell or tissue relative to a cell or tissue derived therefrom.

5. The nucleic acid sequence of claim 1, wherein said synonymous codons for selective 30 expression of said protein are selected from the group consisting of gca (Ala), cuu (Leu) and cua (Leu), and said target is a differentiated cell. SUBSTITUTE SHEET (RULE 26) WO 99/02694 74 PCT/AU98/00530

6. The nucleic acid sequence of claim 5, wherein said differentiated cell is a differentiated keratinocyte.

7. The nucleic acid sequence of any one of 5 claims 2 to 4, wherein said corresponding iso-tRNA in said target cell or tissue is at a level which is at least 110%, preferably at least 200%, more preferably at least 500%, and most preferably at least 1000%, of that expressed in the or each other cell or tissue of 10 the mammal.

8. The nucleic acid sequence of claim 1, wherein the synonymous codon may be selected from the group consisting of (1) a codon used at relatively high frequency by genes, preferably highly expressed 15 genes, of the target cell or tissue, (2) a codon used at relatively high frequency by genes, preferably highly expressed genes, of the or each other cell or tissue, (3) a codon used at relatively high frequency by genes, preferably highly expressed genes, of the 20 mammal, (4) a codon used at relatively low frequency by genes of the target cell or tissue, (5) a codon used at relatively low frequency by genes of the or each other cell or tissue, (6) a codon used at relatively low frequency by genes of the mammal, (7) a 25 codon used at relatively high frequency by genes of another organism, and (8) a codon used at relatively low frequency by genes of another organism.

9. The nucleic acid sequence of claim 1, wherein the at least one existing codon and the 30 synonymous codon are selected such that said protein is expressed from said synthetic nucleic acid sequence in said target cell or tissue at a level which is at SUBSTITUTE SHEET (RULE 26) WO 99/02694 75 PCT/AU98/00530 least 110%, preferably at least 200%, more preferably at least 500%, and most preferably at least 1000%, of that expressed from said parent nucleic acid sequence in said target cell or tissue. 5

10. A method for selectively expressing a protein in a target cell or tissue of a mammal, wherein said selective expression is effected by replacing at least one existing codon of a parent nucleic acid sequence with a synonymous codon to form 10 said synthetic nucleic acid sequence.

11. The method of claim 10, wherein said method is further characterized the steps of: (a) replacing at least one existing codon of a parent nucleic acid sequence encoding said 15 protein with a synonymous codon to produce a synthetic nucleic acid sequence having altered translational kinetics compared to said parent nucleic acid sequence such that said protein is selectively expressible in said target cell or tissue; 20 (b) administering to the mammal and introducing into said target cell or tissue, or a precursor cell or precursor tissue thereof, said synthetic nucleic acid sequence operably linked to one or more regulatory nucleotide sequences; and 25 (c) selectively expressing said protein in said target cell or tissue.

12. The method of claim 11 further including, prior to step (a): (i) measuring relative abundance of 30 different iso-tRNAs in said target cell or tissue, and in one or more other cells or tissues of the mammal; and SUBSTITUTE SHEET (RULE 26) WO 99/02694 76 PCT/AU98/00530 (ii) identifying said at least one existing codon and said synonymous codon based on said measurement, wherein said synonymous codon corresponds to an iso-tRNA which, when compared to an iso-tRNA 5 corresponding to the existing codon, is in higher abundance in said target cell or tissue relative to the or each other cell or tissue of the mammal.

13. The method of claim 12, wherein step (ii) is further characterized in that said synonymous codon 10 corresponds to an iso-tRNA which, when compared to an iso-tRNA corresponding to the at least one existing codon, is in higher abundance in the target cell or tissue relative to a precursor cell or tissue.

14. The method of claim 12, wherein step (ii) 15 is further characterized in that said synonymous codon corresponds to an iso-tRNA which, when compared to an iso-tRNA corresponding to the at least one existing codon, is in higher abundance in the target cell or tissue relative to a cell or tissue derived therefrom. 20

15. The method of claim 11 further including, prior to step (a), identifying said at least one existing codon and said synonymous codon based on respective relative frequencies of particular codons used by genes selected from the group consisting of 25 (I) genes of the target cell or tissue, (II) genes of the or each other cell or tissue, (III) genes of the mammal, and (IV) genes of another organism.

16. A method for expressing a protein in a target cell or tissue from a first nucleic acid 30 sequence including the steps of: introducing into said target cell or tissue, or a precursor cell or precursor tissue SUBSTITUTE SHEET (RULE 26) WO 99/02694 77 PCT/AU98/00530 thereof, a second nucleic acid sequence encoding at least one isoaccepting transfer RNA wherein said second nucleic acid sequence is operably linked to one or more regulatory nucleotide sequences, and wherein 5 said at least one isoaccepting transfer RNA is normally in relatively low abundance in said target cell or tissue and corresponds to a codon of said first nucleic acid sequence.

17. A method for producing a virus particle in 10 a cycling eukaryotic cell, said virus particle comprising at least one protein necessary for assembly of said virus particle, wherein said at least one protein is not expressed in said cell from a parent nucleic acid sequence at a level sufficient to permit 15 virus assembly therein, said method including the steps of: (a) replacing at least one existing codon of said parent nucleic acid sequence with a synonymous codon to produce a synthetic nucleic acid sequence 20 having altered translational kinetics compared to said parent nucleic acid sequence such that said at least one protein is expressible from said synthetic nucleic acid sequence in said cell at a level sufficient to permit virus assembly therein; 25 (b) introducing into said cell or a precursor thereof said synthetic nucleic acid sequence operably linked to one or more regulatory nucleotide sequences; and (c) expressing said at least one protein 30 in said cell in the presence of other viral proteins required for assembly of said virus particle to thereby produce said virus particle. SUBSTITUTE SHEET (RULE 26) WO 99/02694 78 PCT/AU98/00530

18. A method for producing a virus particle in a cycling cell, said virus particle comprising at least one protein necessary for assembly of said virus particle, wherein said at least one protein is not 5 expressed in said cell from a parent nucleic acid sequence at a level sufficient to permit virus assembly therein, and wherein at least one existing codon of said parent nucleic acid sequence is rate limiting for the production said at least one protein 10 to said level, said method including the step of introducing into said cell a nucleic acid sequence capable of expressing therein an isoaccepting transfer RNA specific for said at least one codon.

19. A vector comprising a nucleic acid sequence 15 according to any of claims 1 to 9 wherein said synthetic nucleic acid sequence is operably linked to one or more regulatory nucleic acid sequences.

20. A pharmaceutical composition comprising a nucleic acid sequence according to any of claims 1 to 20 9 together with a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising a vector according to claim 19 together with a pharmaceutically acceptable carrier.

22. A cell or tissue comprising therein a 25 nucleic acid sequence according to any of claims 1 to 9.

23. A cell or tissue comprising therein a vector according to claim 19.

24. A cell or tissue resulting from a method 30 according to any one of claims 10 to 18.

25. Virus particles produced from a method according to claims 17 or 18. SUBSTITUTE SHEET(RULE 26)